Radius Recycling 10-K 26 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 26, 2014	Jun. 30, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'Radius Health, Inc.	'	'
Entity Central Index Key	'0001428522	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$0
Entity Common Stock, Shares Outstanding	'	879,370	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$12,303,000	$18,653,000
Marketable securities	'	4,000,000
Prepaid expenses and other current assets	334,000	2,463,000
Total current assets	12,637,000	25,116,000
Property and equipment, net	76,000	139,000
Other assets	45,000	45,000
Total assets	12,758,000	25,300,000
Current liabilities:	'	'
Accounts payable	300,000	550,000
Accrued expenses and other current liabilities	22,007,000	8,740,000
Current portion of note payable, net of discount	13,005,000	7,800,000
Total current liabilities	35,312,000	17,090,000
Note payable, net of current portion and discount	'	13,005,000
Warrant liability	1,945,000	830,000
Other liabilities	'	24,387,000
Commitments and contingencies	'	'
Stockholders' deficit:	'	'
Common stock, $.0001 par value; 100,000,000 shares authorized, 879,370 and 867,204 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively	'	'
Accumulated deficit	-277,301,000	-200,661,000
Total stockholders' deficit	-277,301,000	-200,661,000
Total liabilities, convertible preferred stock and stockholders' deficit	12,758,000	25,300,000
Series B Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	43,892,000	'
Stockholders' deficit:	'	'
Total stockholders' deficit	43,892,000	'
Series A-1 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	78,737,000	71,957,000
Stockholders' deficit:	'	'
Total stockholders' deficit	78,737,000	71,957,000
Series A-2 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	93,977,000	86,714,000
Stockholders' deficit:	'	'
Total stockholders' deficit	93,977,000	86,714,000
Series A-3 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	12,232,000	11,182,000
Stockholders' deficit:	'	'
Total stockholders' deficit	12,232,000	11,182,000
Series A-4 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	271,000	271,000
Stockholders' deficit:	'	'
Total stockholders' deficit	271,000	271,000
Series A-5 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	525,000	525,000
Stockholders' deficit:	'	'
Total stockholders' deficit	525,000	525,000
Series A-6 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	23,168,000	'
Stockholders' deficit:	'	'
Total stockholders' deficit	$23,168,000	'

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	879,370	867,204
Common stock, shares outstanding	879,370	867,204
Series B Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	980,000	980,000
Preferred Stock, shares issued	701,235	0
Preferred Stock, shares outstanding	701,235	0
Series A-1 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	1,000,000	1,000,000
Preferred Stock, shares issued	939,612	939,612
Preferred Stock, shares outstanding	939,612	939,612
Series A-2 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	983,213	983,213
Preferred Stock, shares issued	983,208	983,208
Preferred Stock, shares outstanding	983,208	983,208
Series A-3 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	142,230	142,230
Preferred Stock, shares issued	142,227	142,227
Preferred Stock, shares outstanding	142,227	142,227
Series A-4 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	4,000	4,000
Preferred Stock, shares issued	3,998	3,998
Preferred Stock, shares outstanding	3,998	3,998
Series A-5 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	7,000	7,000
Preferred Stock, shares issued	6,443	6,443
Preferred Stock, shares outstanding	6,443	6,443
Series A-6 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	800,000	800,000
Preferred Stock, shares issued	496,111	0
Preferred Stock, shares outstanding	496,111	0

Statements_of_Operations_and_C

Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
OPERATING EXPENSES:	'	'	'
Research and development	$60,536	$54,961	$36,179
General and administrative	6,829	9,469	5,330
Loss from operations	-67,365	-64,430	-41,509
OTHER (EXPENSE) INCOME:	'	'	'
Other income (expense), net	9,085	-2,095	-236
Interest income	30	64	27
Interest expense	-2,440	-2,667	-758
NET LOSS	-60,690	-69,128	-42,476
OTHER COMPREHENSIVE LOSS, NET OF TAX:	'	'	'
Unrealized (loss) gain from available-for-sale securities	'	-5	8
COMPREHENSIVE LOSS	-60,690	-69,133	-42,468
(LOSS) EARNINGS ATTRIBUTABLE TO COMMON STOCKHOLDERS - BASIC AND DILUTED (Note 15)	($78,161)	($83,120)	$253
(LOSS) EARNINGS PER SHARE:	'	'	'
Basic (in dollars per share)	($89.43)	($98.99)	$0.51
Diluted (in dollars per share)	($89.43)	($98.99)	$0.07
WEIGHTED AVERAGE SHARES:	'	'	'
Basic (in shares)	874,004	839,698	499,944
Diluted (in shares)	874,004	839,698	3,454,276

Statements_of_Convertible_Pref

Statements of Convertible Preferred Stock, Redeemable Convertible Preferred Stock and Stockholders' Deficit (USD $)

Total

Common Stock

Additional Paid-In-Capital

Accumulated Other Comprehensive Income (Loss)

Accumulated Deficit

Series A-1 Convertible Preferred Stock

Series A-2 Convertible Preferred Stock

Series A-3 Convertible Preferred Stock

Series A-4 Convertible Preferred Stock

Series A-5 Convertible Preferred Stock

Series A-6 Convertible Preferred Stock

Series A Convertible Preferred Stock

New Series B

Series C Convertible Preferred Stock

In Thousands, except Share data, unless otherwise specified

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Balance at Dec. 31, 2010

($128,252)

'

$3

($3)

($128,252)

'

'

'

'

'

'

$93

$38,309

$105,434

Balance (in shares) at Dec. 31, 2010

'

322,807

'

'

'

'

'

'

'

'

'

61,664

1,599,997

10,146,629

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-42,476

'

'

'

-42,476

'

'

'

'

'

'

'

'

'

Unrealized gain from available-for-sale securities

8

'

'

8

'

'

'

'

'

'

'

'

'

'

Forced conversion to common stock

554

'

554

'

'

'

'

'

'

'

'

-33

-296

-225

Forced conversion to common stock (in shares)

'

102,767

'

'

'

'

'

'

'

'

'

-21,661

-177,697

-314,496

Recapitalization

[1]

60,981

'

8,269

'

52,712

'

75,979

9,629

271

'

'

-60

-39,183

-108,425

Recapitalization (in shares)

[1]

'

'

'

'

'

'

983,208

142,227

3,998

'

'

-40,003

-1,422,300

-9,832,133

Stock options exercised

204

'

204

'

'

'

'

'

'

'

'

'

'

'

Stock options exercised (in shares)

'

219,825

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of preferred stock

'

'

'

'

'

62,297

'

'

'

525

'

'

'

'

Issuance of preferred stock (in shares)

'

'

'

'

'

922,286

'

'

'

6,443

'

'

'

'

Accretion of dividends on preferred stock

-10,933

'

-6,590

'

-4,343

1,968

4,000

579

'

'

'

'

1,170

3,216

Stock-based compensation expense

304

'

304

'

'

'

'

'

'

'

'

'

'

'

Milestone payment settled in stock

'

'

'

'

'

1,410

'

'

'

'

'

'

'

'

Milestone payment settled in stock (in shares)

'

'

'

'

'

17,326

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2011

-119,610

'

2,744

5

-122,359

65,675

79,979

10,208

271

525

'

'

'

'

Balance (in shares) at Dec. 31, 2011

'

645,399

'

'

'

939,612

983,208

142,227

3,998

6,443

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-69,128

'

'

'

-69,128

'

'

'

'

'

'

'

'

'

Unrealized gain from available-for-sale securities

-5

'

'

-5

'

'

'

'

'

'

'

'

'

'

Stock options exercised

279

'

279

'

'

'

'

'

'

'

'

'

'

'

Stock options exercised (in shares)

'

221,805

'

'

'

'

'

'

'

'

'

'

'

'

Accretion of dividends on preferred stock

-13,992

'

-4,818

'

-9,174

6,282

6,735

974

'

'

'

'

'

'

Stock-based compensation expense

1,795

'

1,795

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2012

-200,661

'

'

'

-200,661

71,957

86,714

11,182

271

525

'

'

'

'

Balance (in shares) at Dec. 31, 2012

'

867,204

'

'

'

939,612

983,208

142,227

3,998

6,443

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-60,690

'

'

'

-60,690

'

'

'

'

'

'

'

'

'

Stock options exercised

13

'

13

'

'

'

'

'

'

'

'

'

'

'

Stock options exercised (in shares)

'

12,166

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of preferred stock

'

'

'

'

'

'

'

'

'

'

23,168

'

41,514

'

Issuance of preferred stock (in shares)

'

'

'

'

'

'

'

'

'

'

496,111

'

701,235

'

Accretion of dividends on preferred stock

-17,471

'

-1,521

'

-15,950

6,780

7,263

1,050

'

'

'

'

2,378

'

Stock-based compensation expense

1,508

'

1,508

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2013

($277,301)

'

'

'

($277,301)

$78,737

$93,977

$12,232

$271

$525

$23,168

'

$43,892

'

Balance (in shares) at Dec. 31, 2013

'

879,370

'

'

'

939,612

983,208

142,227

3,998

6,443

496,111

'

701,235

'

[1]

The recapitalization includes the exchange of Series A, Series B and Series C shares for Series A-4, Series A-3, and Series A-2 shares, respectively, in addition to the 1:10 exchange of Series A-2, Series A-3, and Series A-4 preferred stock, which occurred in conjunction with the Merger, and is more fully described in note 4.

Statements_of_Convertible_Pref1

Statements of Convertible Preferred Stock, Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)	Dec. 31, 2011
Series A-2 Convertible Preferred Stock	'
Exchange ratio	0.1
Series A-3 Convertible Preferred Stock	'
Exchange ratio	0.1
Series A-4 Convertible Preferred Stock	'
Exchange ratio	0.1

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS USED IN OPERATING ACTIVITIES:	'	'	'
Net loss	($60,690)	($69,128)	($42,476)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	27	44	40
Amortization of premium on short-term investments, net	27	101	21
Stock-based compensation expense	1,508	1,795	304
Research and development expense settled in stock	13,118	15,067	10,296
Change in fair value of other current assets, warrant liability and other liability	-9,087	2,069	264
Non-cash interest	387	449	165
Milestone payment settled with stock	'	'	1,410
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses and other current assets	1,721	4,623	-6,463
Other long-term assets	'	35	25
Accounts payable	-250	237	-301
Accrued expenses and other current liabilities	8,222	1,550	819
Net cash used in operating activities	-45,017	-43,158	-35,896
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:	'	'	'
Purchases of property and equipment	-2	-40	-176
Purchases of marketable securities	-17,070	-18,989	-32,479
Sales and maturities of marketable securities	21,043	46,464	8,855
Net cash provided by (used in) investing activities	3,971	27,435	-23,800
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:	'	'	'
Proceeds from exercise of stock options	13	279	204
Net proceeds from the issuance of preferred stock	42,870	'	62,116
Proceeds from note payable	'	12,500	12,500
Discount on note payable	'	'	-366
Deferred financing costs	'	-31	-56
Payments on note payable	-8,187	-3,500	-156
Net cash provided by financing activities	34,696	9,248	74,242
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-6,350	-6,475	14,546
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	18,653	25,128	10,582
CASH AND CASH EQUIVALENTS AT END OF YEAR	12,303	18,653	25,128
SUPPLEMENTAL DISCLOSURES:	'	'	'
Cash paid for interest	1,796	1,801	358
NON-CASH FINANCING ACTIVITIES:	'	'	'
Accretion of dividends on preferred stock	17,471	13,992	10,933
Fair value of preferred stock issued in the recapitalization	'	'	85,879
Fair value of series A-6 convertible preferred stock issued as settlement of liability	23,168	'	'
Fair value of warrants issued	$1,356	$379	$463

Nature_of_Business

Nature of Business	12 Months Ended
	Dec. 31, 2013
Nature of Business	'
Nature of Business	'
	1. Nature of Business
	Radius Health, Inc. ("Radius" or the "Company"), which was formerly known as MPM Acquisition Corp., is a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company's lead product candidate is abaloparatide (BA058), a bone anabolic for the treatment of osteoporosis delivered via subcutaneous injection, which the Company refers to as Abaloparatide-SC. The Company is currently in Phase 3 development of Abaloparatide-SC and expects to announce top-line data from this study in late 2014. If the results are positive, the Company plans to submit a new drug application in the United States, and a marketing authorization application in Europe in mid-2015. The Company holds worldwide commercialization rights to Abaloparatide-SC, other than in Japan, and with a favorable regulatory outcome, anticipates its first commercial sales of Abaloparatide-SC will take place in 2016. The Company is leveraging its investment in Abaloparatide-SC to develop Abaloparatide-TD. The Company expects this line extension will provide improved patient convenience by enabling administration of abaloparatide through a short-wear-time transdermal patch. The Company has recently completed a successful Phase 2 proof of concept study.
	The Company's current clinical product portfolio also includes a novel oral agent, RAD1901, a selective estrogen receptor down-regulator/degrader, or SERD. The Company is developing RAD1901 at higher doses, for the treatment of breast cancer brain metastases ("BCBM") and at lower doses as a selective estrogen-receptor modulator ("SERM") for the treatment of vasomotor symptoms such as hot flashes. In 2014, the Company expects to commence a Phase 1 clinical trial to evaluate RAD1901 for the treatment of BCBM and previously completed a successful Phase 2 clinical trial of RAD1901 for the treatment of vasomotor symptoms.
	Pursuant to an Agreement and Plan of Merger (the "Merger Agreement" or the "Merger") entered into in April 2011 by and among the Company (a public-reporting, Form 10 shell company at the time), RHI Merger Corp., a Delaware corporation and wholly owned subsidiary of the Company ("MergerCo"), and Radius Health, Inc., a privately-held Delaware corporation ("Former Operating Company"), MergerCo merged with and into the Former Operating Company, with the Former Operating Company remaining as the surviving entity and a wholly-owned subsidiary of the Company. This transaction is herein referred to as the "Merger." The Merger was effective as of May 17, 2011, upon the filing of a certificate of merger with the Delaware Secretary of State. Following the Merger on May 17, 2011, the Company's Board of Directors approved a transaction pursuant to which the Former Operating Company merged with and into the Company, leaving the Company as the surviving corporation (the "Short-Form Merger"). As part of the Short-Form Merger, the Company, then named MPM Acquisition Corp., changed its name to Radius Health, Inc. and assumed the operations of the Former Operating Company.
	The Company is subject to the risks associated with emerging companies with a limited operating history, including dependence on key individuals, a developing business model, market acceptance of the Company's product candidates, competition for its product candidates, and the continued ability to obtain adequate financing to fund the Company's future operations. The Company has incurred losses and expects to continue to incur additional losses for the foreseeable future. As of December 31, 2013, the Company had an accumulated deficit of $277.3 million and believed that its cash and cash equivalents at December 31, 2013 were not sufficient to fund its operations through the first quarter of 2014. However, on February 14, 2014, the Company entered into a Series B-2 Convertible Preferred Stock and Warrant Purchase Agreement (the "Series B-2 Purchase Agreement"), pursuant to which the Company may raise up to approximately $40.2 million through the issuance of (1) up to 655,000 shares of its Series B-2 convertible preferred stock (the "Series B-2 Shares") and (2) warrants to acquire up to 1,637,500 shares of its common stock with an exercise price of $6.142 per share. On February 14, 2014, February 19, 2014 and February 24, 2014, the Company consummated closings under the Series B-2 Purchase Agreement, whereby, in exchange for aggregate proceeds to the Company of approximately $25.6 million, the Company issued an aggregate of 417,615 Series B-2 Shares and warrants to purchase up to a total of 1,044,039 shares of its common stock. See note 19 for additional information regarding the issuance of the Series B-2 Shares.
	The Company believes that the aggregate proceeds from the closings under the Series B-2 Purchase Agreement on February 14, 2014, February 19, 2014 and February 24, 2014, together with its existing cash and cash equivalents will be sufficient to fund its operations into the third quarter of 2014. Accordingly, the Company expects to pursue additional financing opportunities to address its capital needs, including the completion of a private placement or public offering and other strategic financing alternatives that could include, but are not limited to, partnering or other collaboration agreements. However, there is no guarantee that any of these financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical and clinical trials and obtain approval of any product candidates from the U.S. Food and Drug Administration or other regulatory authorities. In addition, the Company could be forced to discontinue product development, reduce or forego sales and marketing efforts, forego attractive business opportunities or discontinue operations entirely. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. Accordingly, the continuation of the Company as a going concern is dependent upon its ability to identify future investment opportunities and obtain the necessary debt or equity financing to support future operations. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Use of Estimates—The preparation of financial statements in conformity with accounting principles generally accepted in the United States ("GAAP") requires the Company's management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued as additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated up to the date of issuance of these financial statements.
	Cash Equivalents—The Company considers all highly liquid investment instruments with an original maturity when purchased of three months or less to be cash equivalents. Cash equivalents at December 31, 2013 and December 31, 2012 are primarily comprised of money market funds.
	Marketable Securities—All investment instruments with an original maturity date, when purchased, in excess of three months have been classified as current marketable securities. These marketable securities are classified as available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are included within other comprehensive (loss) income within stockholders' deficit. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Realized gains and losses on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific identification method. The Company periodically reviews the portfolio of securities to determine whether an other-than-temporary impairment has occurred. No such losses have occurred to date. There were no realized gains or losses on the sale of securities for the years ended December 31, 2013 and 2012.
	Fair Value Measurements—The Company determines the fair market values of its financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following are three levels of inputs that may be used to measure fair value:
	Level 1	Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2	Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Concentrations of Credit Risk and Off-Balance-Sheet Risk—Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale marketable securities. The Company mitigates its risk with respect to cash and cash equivalents and marketable securities by maintaining its deposits and investments at high-quality financial institutions. The Company invests any excess cash in money market funds and other securities, and the management of these investments is not discretionary on the part of the financial institution. The Company's credit exposure on its marketable securities is limited by its diversification among United States government and agency debt securities. The Company has no significant off-balance-sheet risks such as foreign exchange contracts, option contracts, or other hedging arrangements.
	Property and Equipment—Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets.
	Research and Development Costs—The Company accounts for research and development costs by expensing such costs to operations as incurred. Research and development costs primarily consist of clinical testing costs, including payments in cash and stock made to contracted research organizations, personnel costs, outsourced research activities, laboratory supplies, and license fees.
	Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
	Licensing Agreements—Costs associated with licenses of technology are expensed as incurred, and are included in research and development expenses.
	Impairment of Long-Lived Assets—The Company evaluates long-lived assets for potential impairment when there is evidence that events or changes in circumstances have occurred that indicate that the carrying amount of a long-lived asset may not be recovered. Recoverability of these assets is assessed based on the undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends, and product development cycles. Impairment in the carrying value of each asset is assessed when the undiscounted expected future cash flows derived from the asset are less than its carrying value.
	An impairment loss would be recognized in an amount equal to the excess of the carrying amount over the undiscounted expected future cash flows. No impairment charges have been recognized since the Company's inception.
	Segment Information—Operating segments are defined as components of an enterprise engaged in business activities for which discrete financial information is available and regularly reviewed by the chief decision maker in determining how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating segment and operates in one geographic area.
	Income Taxes—The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as operating loss and tax credit carry forwards. The Company measures deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization. The effect on deferred tax assets and liabilities as a result of a change in tax rates is recognized as income in the period that includes the enactment date.
	The Company uses judgment to determine the recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Any material interest and penalties related to unrecognized tax benefits are recognized in income tax expense.
	Due to uncertainty surrounding the realization of the favorable tax attributes in future tax returns the Company has recorded a full valuation allowance against otherwise realizable net deferred tax assets as of December 31, 2013 and 2012.
	Financial Instruments Indexed to and Potentially Settled in the Company's Common Stock —The Company evaluates all financial instruments issued in connection with its equity offerings when determining the proper accounting treatment for such instruments in the Company's financial statements. The Company considers a number of generally accepted accounting principles to determine such treatment and evaluates the features of the instrument to determine the appropriate accounting treatment. The Company utilizes the Black-Scholes method or other appropriate methods to determine the fair value of its derivative financial instruments. Key valuation factors in determining the fair value include, but are not limited to, the current stock price as of the date of measurement, the exercise price, the remaining contractual life, expected volatility for the instrument and the risk-free interest rate. For financial instruments that are determined to be classified as liabilities on the balance sheet, changes in fair value are recorded as a gain or loss in the Company's statement of operations, with the corresponding amount recorded as an adjustment to the liability on its balance sheet.
	Stock-Based Compensation—The Company measures stock-based compensation cost at the accounting measurement date based on the fair value of the option, and recognizes the expense on a straight-line basis over the requisite service period of the option, which is typically the vesting period. The Company estimates the fair value of each option using a Black-Scholes option pricing model that takes into account the fair value of its common stock, the exercise price, the expected life of the option, the expected volatility of the Company's common stock, expected dividends on the Company's common stock, and the risk-free interest rate over the expected life of the option. Due to its limited history, the Company uses the simplified method described in the SEC's Staff Accounting Bulletin No. 107, Share-Based Payment, to determine the expected life of the option grants. The Company's estimate of expected volatility is based on a review of the historical volatility of similar publicly held companies in the biotechnology field over a period commensurate with the option's expected term. The Company has never declared or paid any cash dividends on its common stock and does not expect to do so in the foreseeable future. Accordingly, the Company utilizes an expected dividend yield of zero. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant valuation for a period commensurate with the option's expected term. These assumptions are highly subjective and changes in them could significantly impact the value of the option and hence the related compensation expense.
	The Company applies an estimated forfeiture rate to current period expense to recognize compensation expense only for those awards expected to vest. Estimated forfeitures are based upon historical data, adjusted for known trends, and will be adjusted if actual forfeitures differ or are expected to differ from such estimates. Subsequent changes in estimated forfeitures are recognized through a cumulative adjustment in the period of change and also will impact the amount of stock-based compensation expense in future periods.
	Stock-based compensation expense for options granted to consultants is also determined based upon the fair value of the options issued, as determined by the Black-Scholes option pricing model. However, the unvested portion of such option grants is re-measured at each reporting period, until such time as the award is fully vested.
	Net (Loss) Income Per Common Share—Net (loss) income per common share is calculated using the two-class method, which is an earnings allocation formula that determines net (loss) income per share for the holders of the Company's common shares and participating securities. All of the Company's series of preferred stock contain participation rights in any dividend paid by the Company and are deemed to be participating securities. Net income available to common shareholders and participating preferred shares is allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss.
	Diluted net income per share is computed using the more dilutive of (a) the two-class method, or (b) the if-converted method. The Company allocates net income first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares outstanding gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, and potential issuance of stock upon the issuance of the Company's series A-6 convertible preferred stock ("Series A-6") as settlement of the liability to Nordic Bioscience ("Nordic"). Common equivalent shares are excluded from the computation of diluted net income per share if their effect is anti-dilutive.
	Comprehensive (Loss) Income—Comprehensive (loss) income refers to revenues, expenses, gains and losses that are excluded from net income, as these amounts are recorded directly as an adjustment to stockholders' deficit, net of tax. The Company's other comprehensive (loss) income is comprised of unrealized gains (losses) on its available-for-sale securities.
	Accounting Standards Updates—In July 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists ("ASU 2013-11"). ASU 2013-11 clarifies guidance and eliminates diversity in practice on the presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments under ASU 2013-11 are effective for interim and annual fiscal periods beginning after December 15, 2013, with early adoption permitted. The Company does not expect adoption of ASU 2013-11 will have a material impact on its results of operations, financial position, or cash flows.
	In December 2013, the FASB issued Accounting Standards Update No. 2013-12, Definition of a Public Business Entity ("ASU 2013-12"). ASU 2013-12 amends the Master Glossary of the FASB Accounting Standards Codification to include one definition of public business entity for future use in GAAP. ASU 2013-12 does not affect existing requirements but will be used in considering the scope of new financial guidance and will identify whether the guidance does or does not apply to public business entities. There is no actual effective date for the amendment in ASU 2013-12 and the Company does not expect ASU 2013-12 will have a material impact on its results of operations, financial position or cash flows.
	Recently Adopted Accounting Standards—In February 2013, FASB issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income ("ASU 2013-02"). Under ASU 2013-02, an entity is required to provide information about amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income, but only if the amount reclassified is required to be reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. ASU 2013-02 does not change the current requirements for reporting net income or other comprehensive income in the financial statements. The Company adopted ASU 2013-02 on January 1, 2013. Its adoption did not have a material impact on the Company's results of operations, financial position or cash flows.

Merger

Merger	12 Months Ended
	Dec. 31, 2013
Merger	'
Merger	'
	3. Merger
	As described in note 1, the Company completed a reverse merger transaction with the Former Operating Company on May 17, 2011, pursuant to which the Company changed its name from MPM Acquisition Corp. to Radius Health, Inc. and assumed the operations of the Former Operating Company. The accompanying financial statements and the related disclosures take into account the Merger and Short-Form Merger transactions. In addition, all historical share and per share amounts in the financial statements relating to the Former Operating Company have been retroactively adjusted for all periods presented to give effect to the 1:15 reverse stock split of all the Former Operating Company's capital stock (the "Reverse Stock Split"), including reclassifying an amount equal to the reduction in par value to additional paid-in-capital, approved by the Former Operating Company's Board of Directors prior to the Merger on May 17, 2011.
	As of the effective time of the Merger (the "Effective Time"), the legal existence of MergerCo ceased and all of the shares of the Former Operating Company's common stock, par value $0.01 per share, and shares of the Former Operating Company's preferred stock, par value $0.01 per share, that were outstanding immediately prior to the Merger were cancelled and converted into the right to receive shares of the Company's common or preferred stock, as applicable. Each outstanding share of the Former Operating Company common stock outstanding immediately prior to the Effective Time was automatically converted into the right to receive one share of the Company's common stock, $0.0001 par value per share (the "Common Stock") and each outstanding share of the Company's preferred stock outstanding immediately prior to the Effective Time was automatically converted into the right to receive one-tenth of one share of the Company's preferred stock, $0.0001 par value per share (the "Preferred Stock") as consideration for the Merger.
	The Company assumed all options and warrants of the Former Operating Company outstanding immediately prior to the Effective Time, which became exercisable for shares of the Company's Common Stock or Preferred Stock, as the case may be. Contemporaneously with the closing of the Merger, pursuant to the terms of a Redemption Agreement dated April 25, 2011 by and among the Company and its then-current stockholder, the Company completed the repurchase of 5,000,000 shares of Common Stock from its former sole stockholder in consideration of an aggregate of $50.0 thousand (the "Redemption"). The 5,000,000 shares constituted all of the then issued and outstanding shares of the Company's capital stock, on a fully-diluted basis, immediately prior to the Merger. Upon completion of the Merger and the Redemption, the former stockholders of the Former Operating Company held 100% of the outstanding shares of capital stock of the Company.
	Pursuant to the Merger, the Company assumed all of the Former Operating Company's obligations under its existing contracts. In particular, the Company has assumed the rights and obligations of the Former Operating Company under that certain Series A-1 Convertible Preferred Stock Purchase Agreement, dated as of April 25, 2011, as amended, (the "Purchase Agreement") with certain investors listed therein (the "Investors") pursuant to which, among other things, the Company was obligated to issue and sell to the Investors up to an aggregate of 789,553 shares of Series A-1 convertible preferred stock, par value $0.0001 per share (the "Series A-1"), each at a purchase price per share of $81.42, to be completed in three closings for cash proceeds of $64.3 million. The transactions covered by the Purchase Agreement are referred to herein as the "Series A-1 Financing". An initial closing was completed on May 17, 2011 by the Former Operating Company prior to the Merger.

Recapitalization

Recapitalization	12 Months Ended
	Dec. 31, 2013
Recapitalization	'
Recapitalization	'
	4. Recapitalization
	Subsequent to the Reverse Stock Split and prior to the Merger, the Former Operating Company underwent a recapitalization pursuant to which the preferred stock of the Company (Series A convertible preferred stock ("Series A"), Series B convertible preferred stock ("Series B"), and Series C convertible preferred stock ("Series C"), collectively "Old Preferred Stock") was exchanged for a new series of convertible preferred stock (Series A-2 convertible preferred stock ("Series A-2"), Series A-3 convertible preferred stock ("Series A-3"), Series A-4 convertible preferred stock ("Series A-4"), collectively with Series A-5 convertible preferred stock ("Series A-5"), "New Preferred Stock") to the extent that the existing stockholder participated in the Series A-1 Financing in an amount at least at the level its Pro Rata Share, as defined in the Purchase Agreement. According to the amended Articles of Incorporation of the Former Operating Company, stockholders who did not participate in the Series A-1 Financing in an amount at least equal to their Pro Rata Share amount were subject to a forced conversion (the "Forced Conversion") to common stock, at a rate of 1 share of common stock for every 5 shares of Old Preferred Stock to be so converted. As a result, 21,661 shares of Series A, 177,697 shares of Series B and 314,496 shares of Series C converted into 102,767 shares of the Company's common stock on May 17, 2011.
	The 9,832,133 shares of Series C that remained outstanding after the Forced Conversion, were recapitalized and exchanged for 9,832,133 shares of Series A-2, the 1,422,300 shares of Series B that remained outstanding after the Forced Conversion, were recapitalized and exchanged for 1,422,300 shares of Series A-3, and the 40,003 shares of Series A that remained outstanding after the Forced Conversion, were exchanged for 40,003 shares of Series A-4. All prior dividends that had accrued on the original Series B and Series C through May 17, 2011 were forfeited by the holders as part of the recapitalization. In addition, the holders of the original Series B and Series C waived their contingent redemption rights on such shares.
	Certain investors participated in the Series A-1 Financing in an amount in excess of their Pro Rata Share amount and as consideration for investing such excess amount, received that number of additional shares of Series A-1 as set forth within the Purchase Agreement. The Former Operating Company issued 1,327,506 additional shares of Series A-1 in exchange for this additional investment.
	In accordance with the Purchase Agreement, the Stage I Closing occurred on May 17, 2011 and resulted in net proceeds of $20.3 million as consideration for the issuance of 2,631,845 shares of Series A-1 which were converted in the Merger as described below into the right to receive one-tenth of one share of Series A-1. The issuance of the aforementioned additional shares did not generate a beneficial conversion feature at the date of issuance or at December 31, 2013.
	Subsequent to the recapitalization and financing, pursuant to the Merger, each outstanding share of preferred stock was converted into the right to receive one-tenth of one share of preferred stock. After the recapitalization, Series A-1 and Series A-5 financing (as described in note 3) and the Merger, the Company had the following shares of preferred stock outstanding, which include the shares of Series A-1 issued in the Stage II Closing and Stage III Closing as discussed below:
	Class	Number
		of Shares
	Series A-1		939,612
	Series A-2		983,208
	Series A-3		142,227
	Series A-4		3,998
	Series A-5		6,443
	The Company has accounted for the recapitalization and exchange of the Old Preferred Stock for the New Preferred Stock as an extinguishment of the Old Preferred Stock due to the significance of the changes to the substantive contractual terms of the preferred stock, which included the forfeiture of accrued dividends on the Series A and Series B, the removal of the contingent redemption feature, pursuant to which the Series B and Series C was redeemable at the option of the holder at a future determinable date, and the addition of a mandatory conversion provision to common stock upon the listing of the Company's common stock on a national securities exchange, among other changes. Refer to note 9 for the rights and preferences on the New Preferred Stock. Accordingly, the Company recorded the difference between the fair value of the new shares of preferred stock issued in the exchange and the carrying value of the Old Preferred Stock shares as a gain of $60.9 million that was recorded within stockholders' deficit. The Company allocated $8.3 million to additional paid-in capital to recover the amount of additional paid-in capital that had previously been reduced by dividends accreted on Series B and Series C that was forfeited as part of the recapitalization, and the balance of $52.7 million was recorded to accumulated deficit. The gain on extinguishment is reflected as a preferred stock redemption in the calculation of net income available to common stockholders in accordance with Accounting Standards Codification ("ASC") 260, Earnings Per Share. The fair value of the Series A-1, Series A-2, Series A-3 and Series A-4 was determined using the probability-weighted expected return method (see note 11).
	In connection with the Series A-1 Financing, the Former Operating Company issued to a placement agent, and in the Merger, the Company assumed warrants to purchase 818 shares of Series A-1. The warrants expire on May 17, 2016 and were issued with an exercise price of $81.42, which exercise price, as a result of an anti-dilution adjustment effected in connection with the issuance of the new Series B convertible preferred stock in May 2013 (as described in note 9), has been reduced to $76.27 as of December 31, 2013. The warrants are classified as liabilities on the Company's balance sheet and were recorded as a component of the issuance costs related to the Series A-1 Financing. The Company recorded the warrants at a fair value of $35.0 thousand, calculated using the Black-Scholes option pricing model. The value of the warrants at December 31, 2013 was not material to the financial statements.
	Subsequent to the exchange of outstanding shares of preferred stock for the right to receive one-tenth of one share of Preferred Stock, in accordance with the Purchase Agreement, the Stage II Closing occurred on November 18, 2011 and resulted in net proceeds of approximately $21.0 million through the sale of 263,178 shares of Series A-1. On December 14, 2011, the Stage III Closing occurred resulting in net proceeds of approximately $21.0 million through the sale of 263,180 shares of Series A-1. The issuance of the shares in the Stage II and Stage III Closings did not generate beneficial conversion features at the date of issuance or at December 31, 2013.
	In connection with the Stage II and Stage III Closings, the Former Operating Company issued to a placement agent, warrants to purchase 1,636 shares of Series A-1 Preferred Stock. The warrants expire after five years and were issued with an exercise price of $81.42, which exercise price, as a result of an anti-dilution adjustment effected in connection with the issuance of the new Series B convertible preferred stock in May 2013 (as described in note 9), has been reduced to $76.27 as of December 31, 2013. The warrants are classified as liabilities on the Company's balance sheet and were recorded as a component of the issuance costs related to the Series A-1 Financing. The Company recorded the warrant at a fair value of $68.0 thousand, calculated using the Black- Scholes option pricing model. The value of the warrant at December 31, 2013 was not material to the financial statements.

Marketable_Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2013
Marketable Securities	'
Marketable Securities	'
	5. Marketable Securities
	Available-for-sale marketable securities and cash and cash equivalents consist of the following (in thousands):
		December 31, 2013
		Amortized		Gross		Gross		Fair Value
		Value		Unrealized		Unrealized
				Gains		Losses
	Cash and cash equivalents:
	Cash	$	2,710	$	—	$	—	$	2,710
	Money market		9,593		—		—		9,593
	Total	$	12,303	$	—	$	—	$	12,303
		December 31, 2012
		Amortized		Gross		Gross		Fair Value
		Cost		Unrealized		Unrealized
		Value		Gains		Losses
	Cash and cash equivalents:
	Cash	$	1,134	$	—	$	—	$	1,134
	Money market		16,020		—		—		16,020
	Domestic corporate commercial paper		1,499		—		—		1,499
	Total	$	18,653	$	—	$	—	$	18,653
	Marketable securities:
	Domestic corporate commercial paper		4,000		—		—		4,000
	Total	$	4,000	$	—	$	—	$	4,000
	There were no debt securities that had been in an unrealized loss position for more than or less than 12 months as of December 31, 2013 or December 31, 2012. The contractual term to maturity of all marketable securities held by the Company is less than one year.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property and Equipment	'
Property and Equipment	'
	6. Property and Equipment
	Property and equipment consists of the following (in thousands):
			December 31,
		Estimated Useful Life
		(In Years)	2013			2012
	Furniture and fixtures	5	$	68		$	68
	Computer equipment and software	3		286			284
	Leasehold improvements	Shorter of useful life or remaining lease term		505			505
				859			857
	Less accumulated depreciation and amortization			(783	)		(718	)
	Property and equipment, net		$	76		$	139

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities	'
Accrued Expenses and Other Current Liabilities	'
	7. Accrued Expenses and Other Current Liabilities
	Accrued expenses consist of the following (in thousands):
		December 31,
		2013		2012
	Research costs	$	19,597	$	6,558
	Payroll and employee benefits		1,005		962
	Professional fees		426		399
	Vacation		69		129
	Accrued interest on notes payable		852		595
	Other		58		97
	Total accrued expenses and other current liabilties	$	22,007	$	8,740

Loan_and_Security_Agreement

Loan and Security Agreement	12 Months Ended
	Dec. 31, 2013
Loan and Security Agreement	'
Loan and Security Agreement	'
	8. Loan and Security Agreement
	On May 23, 2011, the Company entered into a loan and security agreement (the "Loan and Security Agreement") with Oxford Finance LLC and General Electric Capital Corporation (collectively, the "Lender") pursuant to which the Lender agreed to lend the Company up to $25.0 million. Upon entering into the Loan and Security Agreement, the Company borrowed $6.3 million from the Lender on May 23, 2011("Term Loan A"), $6.3 million on November 21, 2011 ("Term Loan B") and an additional $12.5 million on May 29, 2012 ("Term Loan C"). The Company's obligations under the Loan and Security Agreement are secured by a first priority security interest in substantially all of the assets of the Company.
	Interest on the outstanding Term Loan A was payable on a monthly basis through and including December 1, 2011. Principal and interest payments on Term Loan A are payable in 36 equal monthly installments beginning December 1, 2011 through November 1, 2014, with a final balloon payment of $0.6 million due upon maturity on November 22, 2014. Interest is payable on Term Loan A at an annual interest rate of 10.16%. Interest on the outstanding Term Loan B was payable on a monthly basis through and including June 1, 2012. Principal and interest payments on Term Loan B are payable in 30 equal monthly installments beginning June 1, 2012, through November 1, 2014, with a final balloon payment of $0.6 million due upon maturity on November 22, 2014. Interest is payable on Term Loan B at an annual interest rate of 10%. Interest on Term Loan C was payable on a monthly basis through, and including, November 1, 2012. Principal and interest payments on Term Loan C are payable in 24 monthly installments beginning December 1, 2012, through November 1, 2014 with a final balloon payment of $1.3 million upon maturity on November 22, 2014. Interest is payable on Term Loan C at an annual interest rate of 10%.
	Upon the last payment date of the amounts borrowed under the Loan and Security Agreement, whether on the maturity date of one of the Term Loans, on the date of any prepayment or on the date of acceleration in the event of a default, the Company will be required to pay the Lender a final payment fee equal to 3.5% of any of the Term Loans borrowed. In addition, if the Company repays all or a portion of the Term Loans prior to maturity, it will pay the Lender a prepayment fee of three percent of the total amount prepaid if the prepayment occurs prior to the first anniversary of the funding of the relevant Term Loan, two percent of the total amount prepaid if the prepayment occurs between the first and second anniversary of the funding of the relevant Term Loan, and one percent of the total amount prepaid if the prepayment occurs on or after the second anniversary of the funding of the relevant Term Loan.
	Upon the occurrence of an event of default, including payment defaults, breaches of covenants, a material adverse change in the collateral, the Company's business, operations or condition (financial or otherwise) and certain levies, attachments and other restraints on the Company's business, the interest rate will be increased by five percentage points and all outstanding obligations will become immediately due and payable. The Loan and Security Agreement also contains a subjective acceleration clause, which provides the Lender the ability to demand repayment of the loan early upon a Material Adverse Change, as defined.
	In connection with each Term Loan, the Company issued Warrants to the Lender to purchase 12,280 shares of the Company's Series A-1 (the "Warrants"). The Warrants are exercisable, in whole or in part, immediately, were issued with a per share exercise price of $81.42 and may be exercised on a cashless basis. The Warrants each have a term of 10 years. The terms of the Warrants provide that the exercise price may be adjusted in the event the Company issues shares of the Series A-1 at a price lower than $81.42 per share. As a result of an anti-dilution adjustment effected in connection with the issuance of the new Series B convertible preferred stock in May 2013 (as described in note 9), the exercise price of the Warrants has been reduced to $76.27 as of December 31, 2013. The Warrants are classified as liabilities in the Company's balance sheet and are re-measured at their estimated fair value at each reporting period. The changes in fair value are recorded as other (expense) income in the statement of operations.
	The initial fair value of the Warrants issued in connection with Term Loan A was $182.6 thousand and was recorded as a discount to Term Loan A. The fair value of the Warrants at December 31, 2013 was $78.1 thousand. The Company also paid the Lender a facility fee of $250.0 thousand and reimbursed the Lender certain costs associated with the Loan and Security Agreement of approximately $117.0 thousand, both of which were also recorded as a discount to Term Loan A. As of December 31, 2013, the discount is being amortized to interest expense over the 42 month period that Term Loan A is expected to be outstanding using the effective interest method.
	The initial fair value of the Warrants issued in connection with Term Loan B (the "Term Loan B Warrants") was $177.6 thousand and was recorded as a discount to Term Loan B. The fair value of the Term Loan B Warrants at December 31, 2013 was $80.1 thousand. The Company also reimbursed the Lender for certain costs associated with Term Loan B of approximately $18.0 thousand, which was also recorded as a discount to Term Loan B. As of December 31, 2013, the discount is being amortized to interest expense over the 36 month period that Term Loan B is expected to be outstanding using the effective interest method.
	The initial fair value of the Warrants issued in connection with Term Loan C (the "Term Loan C Warrants") was $379.7 thousand and was recorded as a discount to Term Loan C. The fair value of the Term Loan C Warrants at December 31, 2013 was $167.9 thousand. The Company also reimbursed the Lender for certain costs associated with the Loan and Security Agreement of approximately $31.0 thousand, which was also recorded as a discount to Term Loan C. As of December 31, 2013, the discount is being amortized to interest expense over the 30 month period that Term Loan C is expected to be outstanding using the effective interest method.
	Future principal payments under the Loan and Security Agreement at December 31, 2013, are as follows (in thousands):
		Principal
		Payments
	Current portion of net payable		13,156
	Discount on current portion of note payable		(151	)
	Current portion of net payable, net of discount	$	13,005

Convertible_Preferred_Stock

Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2013
Convertible Preferred Stock	'
Convertible Preferred Stock	'
	9. Convertible Preferred Stock
	On April 23, 2013, the Company entered into a Series B Convertible Preferred Stock and Warrant Purchase Agreement (the "Series B Purchase Agreement"), pursuant to which the Company could raise, at any time on or prior to May 10, 2013, up to approximately $60.0 million through the issuance of (1) up to 980,000 shares of its new Series B preferred stock (the "New Series B") and (2) warrants to acquire up to 2,450,000 shares of its common stock with an exercise price of $6.142 per share. On April 23, 2013, the Company consummated a first closing under the Series B Purchase Agreement, whereby in exchange for aggregate proceeds of approximately $43.0 million, it issued 700,098 shares of New Series B and warrants to purchase up to a total of 1,750,248 shares of its common stock. On May 10, 2013, the Company consummated a second closing under the Series B Purchase Agreement, whereby in exchange for aggregate proceeds of approximately $0.1 million, it issued 1,137 shares of New Series B and warrants to purchase up to a total of 2,843 shares of its common stock.
	The rights, preferences, and privileges of the New Series B and the Series A-1 Series A-2, Series A-3, Series A-4, Series A-5 and Series A-6 (the Series A-1, Series A-2, Series A-3, Series A-4, Series A-5 and Series A-6, collectively, the "Series A Preferred Stock") as of December 31, 2013, are set forth below.
	Conversion—Each holder of New Series B Shares has the right, at their option at any time, to convert any such shares of New Series B into such number of fully paid shares of common stock as is determined by dividing the original purchase price of $61.42 by the conversion price ("New Series B Optional Conversion"). The conversion price of the New Series B as of December 31, 2013 was $6.142 per share (the "New Series B Conversion Price"), which represents a conversion ratio of one share of New Series B into ten shares of common stock.
	Each holder of Series A-1, Series A-2 and Series A-3 has the right, at their option at any time, to convert any such shares of preferred stock into such number of fully paid shares of common stock as is determined by dividing the original purchase price of $81.42 by the conversion price ("Optional Conversion"). The original conversion price of the Series A-1, Series A-2 and Series A-3 was $8.142 per share (the "Conversion Price"), which represented a conversion ratio of one share of Series A-1, Series A-2 or Series A-3 into ten shares of common stock. The issuance of the New Series B Shares and accompanying warrants under the Series B Purchase Agreement resulted in an adjustment to the Conversion Price of the Series A-1, Series A-2 and Series A-3 (the "Anti-Dilution Adjustment"). As a result of the Anti-Dilution Adjustment, the effective conversion price as of December 31, 2013 of each share of Series A-1, Series A-2 and Series A-3 was reduced to $7.627, which represents a conversion ratio of one share of Series A-1, Series A-2 or Series A-3 into 10.675 shares of common stock.
	Each holder of Series A-4, Series A-5 and Series A-6 has the right, at their option at any time, to convert any such shares of preferred stock into such number of fully paid shares of common stock as is determined by dividing the original purchase price of $81.42 by the conversion price. The conversion price of the Series A-4, Series A-5 and Series A-6 as of December 31, 2013 was $8.142 per share, which represents a conversion ratio of one share of Series A-4, Series A-5 or Series A-6 into ten shares of common stock.
	Upon an optional conversion, the holders of the converted New Series B and Series A Preferred Stock are entitled to payment of all accrued, whether or not declared, but unpaid dividends in shares of the common stock of the Company at the then effective conversion price.
	Each share of the New Series B and Series A Preferred Stock is automatically convertible into fully paid and non-assessable shares of common stock at the applicable conversion price (as described above) in effect upon (1) a vote of the holders of at least 70% of the outstanding shares of New Series B, Series A-1, Series A-2 and Series A-3 to convert all shares of New Series B and Series A Preferred Stock or (2) the common stock becoming listed for trading on a national stock exchange ("Special Mandatory Conversion"). Upon a Special Mandatory Conversion, all accrued, whether or not declared, but unpaid dividends shall be paid in cash or shares of common stock (calculated based on the then effective conversion price) at the discretion of the Company's Board of Directors.
	Redemption—Unless redemption is waived by a requisite stockholder vote or consent, the shares of New Series B and Series A Preferred Stock are automatically redeemable upon an event of sale of the Company. The shares of New Series B and Series A Preferred Stock are not redeemable at the option of the holder.
	Dividends—Holders of shares of New Series B are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of New Series B. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of New Series B are also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of New Series B, holders of shares of Series A-1 are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series A-1. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-1 are also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of New Series B and Series A-1, holders of Series A-2 are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series A-2. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-2 are also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of New Series B, Series A-1 and Series A-2, holders of Series A-3 are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series A-3. Dividends are payable, as accrued, upon liquidation, event of sale and conversion to common stock, as described above. The holders of shares of Series A-3 are also entitled to dividends declared or paid on any shares of common stock.
	Without regard to the payment of required dividends to the holders of New Series B, Series A-1, Series A-2 and Series A-3, holders of Series A-5 are entitled to receive the Series A-5 Special Accruing Dividend (as defined in the Company's certificate of incorporation) paid in shares of Series A-6 as described in note 8. Dividends are payable, as accrued, upon liquidation, event of sale and conversion to common stock, as described above. The holders of shares of Series A-5 are also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of New Series B, Series A-1, Series A-2, Series A-3 and Series A-5, holders of Series A-4 and Series A-6 are entitled to receive, when, if and as declared by the Board of Directors, dividends on any shares of Series A-4 Stock or Series A-6 Stock, as the case may be, out of funds legally available for that purpose, at a rate to be determined by the Board of Directors if and when they may so declare any dividend on the Series A-4 Stock or A-6 Stock, as the case may be. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-4 and Series A-6 are also entitled to dividends declared or paid on any shares of common stock.
	Dividends on the Company's preferred stock are payable, at the sole discretion of the Board of Directors, in cash or in shares of the Company's common stock at the current market price of shares of common stock, when and if declared by the Board of Directors and upon liquidation or an event of sale. All accrued but unpaid dividends on New Series B and Series A Preferred Stock will be paid in cash or shares of common stock, at the then effective Conversion Price of shares of New Series B and Series A Preferred Stock, upon a Special Mandatory Conversion (as defined in the Company's certificate of incorporation). Upon Optional Conversion, dividends are payable in shares of the common stock at the then effective conversion price of shares of preferred stock.
	As of December 31, 2013, the Company had accrued dividends of $2.4 million, $15.0 million, $18.0 million and $2.6 million on New Series B, Series A-1, Series A-2 and Series A-3, respectively.
	Voting—The holders of New Series B and Series A Preferred Stock are entitled to vote together with the holders of the common stock as one class on an as-if converted basis. In addition, as long as the shares of Series A-1 are outstanding, the holders of Series A-1, voting as a separate class, have the right to elect two members of the Company's Board of Directors.
	Liquidation—The shares of New Series B rank senior to the Series A-1 and all other classes of Series A Preferred Stock. The shares of Series A-1 rank senior to all other classes of Series A Preferred Stock. Series A-2 ranks junior to Series A-1 and senior to Series A-3, Series A-4, Series A-5 and Series A-6. Series A-3, Series A-5 and Series A-6 rank equally but junior to Series A-1 and Series A-2 and senior to Series A-4. Series A-4 ranks senior to the Company's common stock.
	In the event of a liquidation, dissolution, or winding-up of the Company, the holders of New Series B are entitled to be paid first out of the assets available for distribution, before any payment is made to the Series A Preferred Stock. Payment to the holders of New Series B shall consist of two (2) times the original purchase price of $61.42, plus all accrued but unpaid dividends. After such distribution to the holders of New Series B, the holders of Series A-1 will be entitled to be paid out of the remaining assets available for distribution, before any payment is made to the Series A-2, Series A-3, Series A-4, Series A-5 and Series A-6. Payment to the holders of Series A-1 shall consist of the original purchase price of $81.42, plus all accrued but unpaid dividends. After the distribution to the holders of Series A-1, the holders of Series A-2 will be entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any accrued but unpaid dividends. After the distribution to the holders Series A-1 and Series A-2, the holders of Series A-3, Series A-5 and Series A-6, will be entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any accrued but unpaid or declared and unpaid dividends, as appropriate. After the distribution to the holders Series A-1, Series A-2, Series A-3, Series A-5 and Series A-6, the holders of Series A-4 will be entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any declared and unpaid dividends. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of New Series B, the assets will be distributed ratably among the holders of New Series B in proportion to their aggregate liquidation preference amounts. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-1, the assets will be distributed ratably among the holders of Series A-1 in proportion to their aggregate liquidation preference amounts. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-2, the assets will be distributed ratably among the holders of Series A-2 in proportion to their aggregate liquidation preference amounts. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-3, Series A-5 and Series A-6, the assets will be distributed ratably among the holders of Series A-3, Series A-5 and Series A-6 in proportion to their aggregate liquidation preference amounts. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-4, the assets will be distributed ratably among the holders of Series A-4 in proportion to their aggregate liquidation preference amounts. After all liquidation preference payments have been made to the holders of the New Series B and Series A Preferred Stock, the holders of the New Series B and Series A-1, Series A-2 and Series A-3 shall participate in the distribution of the remaining assets with the holders of the Company's common stock on an as-if converted basis.
	In the event of, and simultaneously with, the closing of an event of sale of the Company (as defined in the Company's Amended Certificate of Incorporation), the Company shall redeem all of the shares of New Series B and Series A Preferred Stock then outstanding at the Special Liquidation Price, as defined. If the event of sale involves consideration other than cash, the Special Liquidation Price may be paid with such consideration having a value equal to the Special Liquidation Price. The Special Liquidation Price shall be equal to an amount per share, which would be received by each holder of the Preferred Stock if, in connection with the event of sale, all the consideration paid in exchange for the assets or the shares of capital stock of the Company was actually paid to and received by the Company, and the Company was immediately liquidated thereafter and its assets distributed pursuant to the liquidation terms above.

Stockholders_Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2013
Stockholders' Deficit	'
Stockholders' Deficit	'
	10. Stockholders' Deficit
	Common Stock—The Company has reserved the following number of shares of common stock (in thousands):
		December 31,
		2013		2012
	Conversion of New Series B Preferred Stock		9,800		—
	Conversion of Series A-1 Preferred Stock		10,000		10,000
	Conversion of Series A-2 Preferred Stock		9,832		9,832
	Conversion of Series A-3 Preferred Stock		1,422		1,422
	Conversion of Series A-4 Preferred Stock		40		40
	Conversion of Series A-5 Preferred Stock		70		70
	Conversion of Series A-6 Preferred Stock		8,000		8,000
	Stock options and Warrants		18,842		19,656
	Total		58,006		49,020

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Measurements	'
Fair Value Measurements	'
	11. Fair Value Measurements
	The following tables summarize the financial assets and liabilities measured at fair value on a recurring basis in the accompanying balance sheets as of December 31, 2013 and 2012 (in thousands):
		As of December 31, 2013
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash	$	2,710		$	—	$	—	$	2,710
	Money market funds(1)		9,593			—		—		9,593
		$	12,303		$	—	$	—	$	12,303
	Liabilities
	Warrant liability(2)	$	—		$	—	$	1,945	$	1,945
	Stock Liability(2)						$	5,328	$	5,328
		$	—		$	—	$	7,273	$	7,273
		As of December 31, 2012
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash	$	1,134		$	—	$	—	$	1,134
	Money market funds(1)		16,020			—		—		16,020
	Domestic corporate commercial paper(3)		—			1,499		—		1,499
	Marketable Securities:
	Domestic corporate commercial paper(3)		—			4,000		—		4,000
	Stock asset(2)		—			—		407		407
		$	17,154		$	5,499	$	407	$	23,060
	Liabilities
	Warrant liability(2)	$	—		$	—	$	830	$	830
	Other liability(2)		—			—		24,387		24,387
	Stock liability(2)							245		245
		$	—		$	—	$	25,462	$	25,462
	-1
	Fair value is based upon quoted market prices.
	-2
	Fair value is determined using the probability-weighted expected return model ("PWERM"), as discussed below. Changes in the fair value of the Level 3 assets and liabilities are recorded as other (expense) income in the statement of operations.
	-3
	Fair value is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources, including market participants, dealers and brokers.
	The stock asset represents the prepaid balance of the research and development expense related to the stock dividends to be issued to Nordic Bioscience Clinical Development VII A/S ("Nordic") in shares of Series A-6 (or in shares of common stock if the Company lists its common stock on a national exchange) which is being recognized ratably over the estimated per patient treatment period under the three work statements executed with Nordic (the "Nordic Work Statements") (see note 13). The stock liability represents the accrued balance of the research and development expense related to the stock dividends to be issued to Nordic in shares of Series A-6 (or in shares of common stock if the Company lists its common stock on a national exchange) which is being recognized ratably over the estimated per patient treatment period under the Nordic Work Statements.
	The fair values of the stock asset and stock liability are based upon the fair value of the Series A-6 as determined using PWERM, which considers the value of the Company's various classes of preferred stock. The fair value of the Company's various classes of preferred stock is determined through an analysis of the future values for equity assuming various future outcomes. Accordingly, share value is based upon the probability weighted present value of expected future net cash flows, considering each of the possible future events, discount rate as determined using the capital asset pricing model, as well as the rights and preferences of each share class. PWERM is complex as it requires numerous assumptions relating to potential future outcomes of equity. Accordingly, the valuation of the Company's stock asset and stock liability is determined using Level 3 inputs.
	The warrant liability represents the liability for the warrants issued to the placement agent in connection with the Company's Series A-1 financing, to the investors in the New Series B financing in April and May 2013, and to the lenders in connection with the Company's Loan and Security Agreement executed with Oxford Finance LLC and General Electric Capital Corporation in May 2011. The warrant liability is calculated using the Black-Scholes option pricing method. This method of valuation includes using inputs such as the fair value of the Company's common stock or preferred stock, historical volatility, the term of the warrant and risk free interest rates. The fair value of the Company's shares of common stock and preferred stock is estimated using PWERM, as described above. Accordingly, the valuation of the warrant liability is determined using Level 3 inputs.
	The other liability represents the liability to issue shares of Series A-6 for services rendered in connection with the Nordic Work Statements. The liability is calculated based upon the number of shares earned by Nordic through the performance of clinical trial services multiplied by the estimated fair value of the Company's Series A-6 at each reporting date. The estimated fair value of the Series A-6 is determined using PWERM, as described above. Accordingly, the valuation of the other liability is determined using Level 3 inputs.
	As noted above, the Company's Level 3 fair value measurements related to its stock asset, stock liability, warrant liability and other liability are based upon the fair value of the Company's common stock and preferred stock. The following table provides quantitative information about the fair value measurement of the Company's common stock and preferred stock, including significant unobservable inputs:
	Instrument	Valuation		Unobservable Input		Estimate
		Technique
	Preferred Stock	PWERM		•		•
				Time until future exit event (years)		0.0 - 0.4
				•		•
				Probability of abaloparatide coming to market		65% - 75%
				•		•
				Discount rate		20% - 40%
				•		•
				Long-term revenue growth rate(1)		2% - 117%
				•		•
				Long-term pre-tax operating margin(2)		13% - 79%
				•		•
				Discount for lack of marketability		10% - 36%
		Market Comparable Companies		•		•
				Revenue multiple(3)		3.2 - 8.0
	-1
	Estimated long-term revenue growth rate has the above range and an average of approximately 27% over 16 revenue years.
	-2
	Estimated long-term pretax operating margin has the above range after achieving positive pretax operating margin and an average of approximately 68% for 17 years.
	-3
	Represents amounts used when the Company has determined that market participants would use such multiples when valuing the Company's preferred stock.
	As of December 31, 2013, the warrant liability and stock liability have fair values of $1.9 million and $5.3 million, respectively. Changes in the significant unobservable inputs used in the fair value measurements of the Company's common stock and preferred stock in isolation would result in a significantly different fair value measurement of the stock asset, stock liability, warrant liability and other liability. Generally, a change in the assumption used for the probability of successful development is accompanied by a directionally similar change in the assumption used for the long-term revenue growth rate and long-term pre-tax operating margin and estimated fair value measurement of the Company's common stock and preferred stock.
The following table provides a roll forward of the fair value of the assets, where fair value is determined using Level 3 inputs (in thousands):
Balance at January 1, 2012	$	3,379
Expense recognized		(4,080	)
Additions		398
Change in fair value		710
Balance at December 31, 2012	$	407
Expense recognized		(313	)
Additions		86
Change in fair value		(180	)
Balance at December 31, 2013	$	—
The following table provides a roll forward of the fair value of the liabilities, where fair value is determined using Level 3 inputs (in thousands):
Balance at January 1, 2012	$	10,920
Additions		11,763
Change in fair value		2,779
Balance at December 31, 2012	$	25,462
Issuance of shares of Series A-6		(23,168	)
Additions		14,246
Change in fair value		(9,267	)
Balance at December 31, 2013	$	7,273
Additions represent the value of the asset or liability for additional accrued shares of stock issuable to Nordic for services rendered in connection with the Company's Phase 3 clinical study of Abaloparatide-SC and Phase 2 clinical study of Abaloparatide-TD (see note 13), as well as the value of any new warrants issued during the period. The issuance of shares of Series A-6 represent the release in the quarterly stock dividends of Series A-6 accrued under the Nordic Work Statements as of December 31, 2013 (see note 13).
The fair value of the Company's note payable is determined using current applicable rates for similar instruments as of the balance sheet date. The carrying value of the Company's note payable approximated its fair value as of December 31, 2013, as the Company's interest rate is near current market rates. The fair value of the Company's notes payable was determined using Level 3 inputs.

License_Agreements

License Agreements	12 Months Ended
	Dec. 31, 2013
License Agreements	'
License Agreements	'
	12. License Agreements
	On September 27, 2005, the Company entered into a license agreement (the "Ipsen Agreement"), as amended, with SCRAS S.A.S, a French corporation on behalf of itself and its affiliates (collectively, "Ipsen"). Under the Ipsen Agreement, Ipsen granted to the Company an exclusive right and license under certain Ipsen compound technology and related patents to research, develop, manufacture and commercialize certain compounds and related products in all countries, except Japan and (subject to certain co-marketing and co-promotion rights retained by Ipsen) France. With respect to France, if Ipsen exercises its co-marketing and co-promotion rights then Ipsen may elect to receive a percentage of the aggregate revenue from the sale of products by both parties in France (subject to a mid-double digit percentage cap) and Ipsen shall bear a corresponding percentage of the costs and expenses incurred by both parties with respect to such marketing and promotion efforts in France; Ipsen shall also pay Radius a mid-single digit royalty on Ipsen's allocable portion of aggregate revenue from the sale of products by both parties in France. Abaloparatide (the Company's bone growth drug) is subject to the Ipsen Agreement. Ipsen also granted the Company an exclusive right and license under the Ipsen compound technology and related patents to make and have made compounds or product in Japan. Ipsen also granted the Company an exclusive right and license under certain Ipsen formulation technology and related patents solely for purposes of enabling the Company to develop, manufacture and commercialize compounds and products covered by the compound technology license in all countries, except Japan and (subject to certain co-marketing and pro-promotion rights retained by Ipsen) France. In consideration for these licenses, the Company made a nonrefundable, non-creditable payment of $250.0 thousand to Ipsen, which was expensed during 2005. The Ipsen Agreement provides for further payments in the range of €10.0 million to €36.0 million ($13.8 million to $49.6 million) to Ipsen upon the achievement of certain development and commercialization milestones specified in the Ipsen Agreement, and for the payment of fixed 5% royalties on net sales of any product by the Company or our sublicensees on a country-by-country basis until the later of the last to expire of the licensed patents or for a period of 10 years after the first commercial sale in such country of any product that includes the compound licensed from Ipsen or any analog thereof.
	If the Company sublicenses the rights licensed from Ipsen, then the Company will also be required to pay Ipsen a percentage of certain payments received from such sublicensee (in lieu of milestone payments not achieved at the time of such sublicense). The applicable percentage is in the low double digit range. In addition, if the Company or its sublicensees commercialize a product that includes a compound discovered by it based on or derived from confidential Ipsen know-how, it will be obligated to pay to Ipsen a fixed low single digit royalty on net sales of such product on a country-by-country basis until the later of the last to expire of its patents that cover such product or for a period of 10 years after the first commercial sale of such product in such country. In connection with the Ipsen Agreement, the Company recorded approximately $0.2 million, $0.7 million and $1.0 million in research and developments costs in the years ended December 31, 2013, 2012 and 2011, respectively. The costs were incurred by Ipsen and charged to the Company for the manufacture of the clinical supply of the licensed compound.
	On May 11, 2011, the Company entered into a second amendment to the Ipsen Agreement pursuant to which Ipsen agreed to accept shares of Series A-1 in lieu of cash as consideration for a milestone payment due to Ipsen following the initiation of the first abaloparatide Phase 3 study. The number of shares of Series A-1 to be issued to Ipsen was determined based upon the U.S. dollar exchange rate for the euro two business days prior to closing. On May 17, 2011, the Company issued 17,326 shares of Series A-1 to Ipsen to settle the obligation. Accordingly, the Company recorded research and development expense of $1.4 million during the year ended December 31, 2011. The expense represents the fair value of the Series A-1 shares of $81.42 per share.

Research_Agreements

Research Agreements	12 Months Ended
	Dec. 31, 2013
Research Agreements	'
Research Agreements	'
	13. Research Agreements
	Abaloparatide-SC Phase 3 Clinical Study—On March 29, 2011, the Company and Nordic entered into a Clinical Trial Services Agreement, a Work Statement NB-1 (the "Work Statement NB-1") under such Clinical Trial Services Agreement and a related Stock Issuance Agreement, as amended to date (the "Stock Issuance Agreement"). Pursuant to the Work Statement NB-1, Nordic is managing the Phase 3 clinical study (the "Phase 3 Clinical Study") of Abaloparatide-SC and is being compensated for such services in a combination of cash and shares of stock.
	In December 2011, the Company entered into an amendment to the Work Statement NB-1(the "First Amendment"). Pursuant to the original terms of the Work Statement NB-1, the study was to be conducted in 10 countries at a specified number of sites within each country. The terms of the First Amendment (1) provided for two additional countries (the United States and India) in which the study would be conducted, (2) specified a certain number of sites within each such additional country for the conduct of the study, and (3) amended various terms and provisions of the Work Statement NB-1 to reflect the addition of such countries and sites within the study's parameters. Payments to be made by the Company to Nordic under the First Amendment are denominated in both euros and U.S. dollars and total up to €717,700 ($988,919) and $289,663, respectively, for the 15 additional study sites in India contemplated by the First Amendment and up to €1.2 million ($1.7 million) and $143,369, respectively, for the five additional study sites in the United States contemplated by the First Amendment.
	In June 2012, the Company entered into a second amendment to the Work Statement NB-1(the "Second Amendment"). Pursuant to the original terms of the Work Statement NB-1, as amended by the First Amendment, the study was to be conducted in 12 countries at a specified number of sites within each country. The terms of the Second Amendment (1) increased the overall number of sites by adding sites in Europe, Brazil and Argentina and removing other sites, (2) specified a certain number of sites within each country for the conduct of the study, and (3) amended various terms and provisions of the Work Statement NB-1 to reflect additional services to be provided at existing sites and the addition of the new study sites within the study's parameters. The Second Amendment also provided that cash payments to Nordic under the Clinical Trial Services Agreement as well as the payment of shares of stock under the related Stock Issuance Agreement will each be reduced by an amount of €11,941 ($16,454) per subject for any subjects enrolled in India or the United States. Such reductions shall be applied in pro rata monthly installments. Payments to be made by the Company to Nordic under the Second Amendment in connection with the additional services provided at existing sites and the conduct of the study at the new study sites are denominated in both euros and U.S. dollars and total of up to €3.7 million ($5.1 million) and $205,540, respectively.
	Pursuant to the Work Statement NB-1, the Company is required to make certain per patient payments denominated in both euros and U.S. dollars for each patient enrolled in the Phase 3 Clinical Study followed by monthly payments for the duration of the study and final payments in two equal euro-denominated installments and two equal U.S. dollar-denominated installments. Changes to the Clinical Study schedule may alter the timing, but not the aggregate amounts of the payments.
	The Work Statement NB-1, as amended on December 9, 2011 and June 18, 2012, provides for a total of up to approximately €41.2 million ($56.7 million) of euro-denominated payments and a total of up to approximately $3.2 million of U.S. dollar-denominated payments over the course of the Phase 3 Clinical Study. These payments may be adjusted based upon actual sites opened, work performed or number of patients enrolled.
	Pursuant to the Stock Issuance Agreement, Nordic agreed to purchase the equivalent of €371,864 of Series A-5 at $8.142 per share, and 64,430 shares of Series A-5 were sold to Nordic on May 17, 2011 for proceeds of $525,154. These shares were exchanged in the Merger for an aggregate of 6,443 shares of the Company's Series A-5.
	The Stock Issuance Agreement provides that Nordic is entitled to receive quarterly stock dividends, payable in shares of Series A-6 or shares of common stock if the Company's preferred stock has been converted in accordance with its amended certificate of incorporation, having an aggregate value of up to €36.8 million ($50.7 million) (the "Nordic Accruing Dividend"). In the event Nordic sells the shares of Series A-5 or in the event the shares of Series A-5 are converted into common stock in accordance with the Company's amended certificate of incorporation, this right to receive the Nordic Accruing Dividend will terminate, but a right to receive an equivalent number of shares of Series A-6 or common stock, as applicable, will remain with Nordic as a contractual right under the Stock Issuance Agreement.
	The Nordic Accruing Dividend related to the Phase 3 Clinical Study is determined based upon the estimated period that will be required to complete the Phase 3 Clinical Study. On the last business day of each calendar quarter (each, an "Accrual Date"), beginning with the quarter ended June 30, 2011, the Company has a liability to issue shares of Series A-6 (or common stock, after the conversion of the Company's preferred stock into common stock) to Nordic that is referred to as the "Applicable Quarterly Amount" and is equal to €36.8 million ($50.7 million) (subject to adjustment in accordance with the applicable provisions of the Second Amendment relating to consideration payable for patients enrolled in India and the U.S.) minus the aggregate value of any prior Nordic Accruing Dividend accrued divided by the number of calendar quarters it will take to complete the Phase 3 Clinical Study. To calculate the aggregate number of shares due to Nordic in each calendar quarter, the Company converts the portion of €36.8 million ($50.7 million) to accrue in such calendar quarter into U.S. dollars using the simple average of the exchange rate for buying U.S. dollars with euros for all Mondays in such calendar quarter. The Company then calculates the aggregate number of shares to accrue in such calendar quarter by dividing the U.S. dollar equivalent of the Applicable Quarterly Amount, by the greater of (1) the fair market value of the Company's common stock as of the applicable Accrual Date or (2) $8.142 and rounding down the resulting quotient to the nearest whole number. Such shares due to Nordic are to be issued when declared or paid by the Company's Board of Directors, who are required to do so upon Nordic's request, or upon an event of sale. As of December 31, 2013, 438,124 shares of Series A-6 were due to Nordic under Work Statement NB-1, as amended, or, after the automatic conversion into common stock of the Company's preferred stock, 4,381,240 shares of the Company's common stock. In December 2013, Nordic requested that all shares of Series A-6 accrued as of December 31, 2013 under Work Statement NB-1 be issued. Accordingly, the Company's Board of Directors declared a dividend to Nordic of all 438,124 shares of Series A-6 accrued under Work Statement NB-1 on December 31, 2013.
	Prior to the issuance of shares of stock to Nordic in satisfaction of the Nordic Accruing Dividend, the liability to issue shares of stock was being accounted for as a liability in the Company's balance sheet, based upon the fair value of the Series A-6 as determined using PWERM. Changes in the fair value from the date of accrual to the date of issuance of the Series A-6 shares are recorded as a gain or loss in other income (expense) in the statement of operations.
	The Company recognizes research and development expense for the amounts due to Nordic under the Work Statement NB-1 ratably over the estimated per patient treatment period beginning upon enrollment in the Phase 3 Clinical Study, or a twenty-month period. The Company recorded $31.6 million, $30.8 million, and $5.1 million of research and development expense during the years ended December 31, 2013, 2012, and 2011, respectively, for per patient costs incurred for patients that had enrolled in the Phase 3 Clinical Study. During the year ended December 31, 2011, the Company also recorded approximately $11.0 million of research and development expense associated with the costs incurred for preparatory and other start-up costs to initiate the Phase 3 Clinical Study.
	As of December 31, 2013, the Company had (1) a liability of $4.8 million reflected in accrued expenses and other current liabilities on the balance sheet resulting from services provided by Nordic, which are payable in the form of a stock dividend and (2) a liability of $11.6 million that is reflected in accrued expenses and other current liabilities on the balance sheet resulting from services provided by Nordic, which are payable in cash.
	Abaloparatide-SC Phase 3 Clinical Extension Study—In February 2013, the Company entered into a Work Statement NB-3 (the "Work Statement NB-3") under the Clinical Trial Services Agreement and the related Stock Issuance Agreement. Pursuant to Work Statement NB-3, Nordic will perform an extension study to evaluate six months of standard-of-care osteoporosis management following the completion of the 18-month Abaloparatide-SC Phase 3 Clinical Study (the "Extension Study") and will be compensated for such services in a combination of cash and shares of stock. Under the terms of a Letter of Intent that the Company entered into with Nordic on October 22, 2012 setting forth the parties' obligations to negotiate in good faith to enter into Work Statement NB-3, the Company was required to make an initial payment of €806,468 ($1.1 million).
	Payments in cash to be made to Nordic under the Work Statement NB-3 are denominated in both euros and U.S. dollars and total up to €4.5 million ($6.2 million) and $0.6 million, respectively. In addition, the Company will issue to Nordic, shares of the Company's Series A-6 having a value of up to €4.5 million ($6.2 million) and $0.3 million, as additional payment for services to be provided under the Work Statement NB-3 and the Services Agreement.
	The Stock Issuance Agreement provides that, beginning with the quarter ended March 31, 2013, Nordic was entitled to receive quarterly stock dividends in connection with services performed under the Work Statement NB-3, payable in shares of Series A-6 or shares of common stock if the Company's preferred stock has been automatically converted into common stock in accordance with its amended certificate of incorporation, having an aggregate value of up to €4.5 million ($6.2 million) and $0.3 million. In the event Nordic sells the shares of Series A-5 or in the event the shares of Series A-5 are converted into common stock in accordance with the Company's amended certificate of incorporation, this right to receive the Nordic Accruing Dividend will terminate, but a right to receive an equivalent number of shares of Series A-6 or common stock, as applicable, will remain with Nordic as a contractual right under the Stock Issuance Agreement.
	The Nordic Accruing Dividend related to the Extension Study is determined based upon the estimated period that will be required to complete the Extension Study. On each Accrual Date, beginning with the quarter ended March 31, 2013, the Company will recognize a liability to issue shares of Series A-6 to Nordic with an Applicable Quarterly Amount value equal to €4.5 million ($6.2 million) and $0.3 million minus the aggregate value of any previously accrued Nordic Accruing Dividend related to the Extension Study divided by the number of calendar quarters it will take to complete the Extension Study. The Company calculates the aggregate number of shares of Series A-6 to accrue in such calendar quarter by dividing such Applicable Quarterly Amount, by the greater of (1) the fair market value of the Company's common stock as of the applicable Accrual Date or (2) $8.142 and rounding down the resulting quotient to the nearest whole number. Such shares due to Nordic are to be issued when declared or paid by the Company's Board of Directors, who are required to do so upon Nordic's request, or upon an event of sale. As of December 31, 2013, 25,772 shares of Series A-6 were due to Nordic under Work Statement NB-3, or, after the automatic conversion into common stock of the Company's preferred stock, 257,720 shares of the Company's common stock. In December 2013, Nordic requested that all shares of Series A-6 accrued as of December 31, 2013 under Work Statement NB-3 be issued. Accordingly, the Company's Board of Directors declared a dividend to Nordic of all 25,772 shares of Series A-6 accrued under Work Statement NB-3 on December 31, 2013.
	Prior to the issuance of the shares of Series A-6 to Nordic in satisfaction of the Nordic Accruing Dividend, the liability to issue shares of stock was being accounted for as a liability in the Company's balance sheet, based upon the fair value of the Series A-6 as determined using PWERM. Changes in the fair value from the date of accrual to the date of issuance of the Series A-6 shares are recorded as a gain or loss in other income (expense) in the statement of operations.
	On December 6, 2013, the Company entered into a Letter of Intent (the "Letter of Intent") with Nordic, which provides that the Company and Nordic will continue to negotiate the definitive terms of an Amendment No. 1 to Work Statement NB-3 (the "Amendment") which provides for an additional 18 months of standard-of-care treatment for those patients enrolled in the Extension Study being performed under Work Statement NB-3 (the "Second Extension"). The Amendment provides for payment by the Company to Nordic of both cash and equity compensation in consideration of the services provided by Nordic, with the equity portion of such compensation to be made pursuant to an Amendment No. 2 to the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011.
	Pursuant to the Letter of Intent, the Company was required to make an initial payment of €222,573 ($0.3 million) and agreed to commence payment of the cash compensation due in consideration of the services being provided by Nordic under the Amendment. Once the Amendment is fully executed, the Company will commence payment of both the cash and equity compensation stipulated under the Amendment.
	Payments in cash to be made by the Company to Nordic under the Letter of Intent and Amendment in connection with the services to be provided are denominated in both euros and U.S. dollars and total up to €3.0 million ($4.1 million) and $0.5 million, respectively. In addition, the Company will issue to Nordic, subject to the execution of the Amendment, shares of its stock having a value of up to €3.0 million ($4.1 million) and $0.5 million, as additional payment for services to be provided under the Amendment and the Services Agreement.
	The Letter of Intent will terminate on the earlier of (1) the date on which the Company and Nordic enter into the Amendment or (2) February 28, 2014 (pursuant to an extension mutually agreed to by the Company and Nordic).
	The Company recognizes research and development expense for the amounts due to Nordic under the Work Statement NB-3 and Amendment ratably over the estimated per patient treatment periods beginning upon enrollment, or over a nine-month and nineteen-month period, respectively. The Company recorded $4.5 million of research and development expense during the year ended December 31, 2013, for per patient costs incurred for patients that had enrolled in the Extension Study and Second Extension.
	As of December 31, 2013, the Company had (1) a liability of $0.6 million reflected in accrued expenses and other current liabilities on the balance sheet resulting from services provided by Nordic, which are payable in the form of a stock dividend and (2) a liability of $0.5 million that is reflected in accrued expenses and other current liabilities on the balance sheet resulting from services provided by Nordic, which are payable in cash.
	Abaloparatide-TD Phase 2 Clinical Study—On July 26, 2012, the Company entered into a Letter of Intent (the "Phase 2 Letter of Intent") with Nordic, which provides that the Company and Nordic will, subject to compliance by the Company with certain requirements of its Certificate of Incorporation and applicable securities laws, negotiate in good faith to enter into (1) a Work Statement NB-2 (the "Work Statement NB-2"), a draft of which is attached to the Phase 2 Letter of Intent, and (2) an amendment to the Amended and Restated Stock Issuance Agreement.
	In February 2013, the Company executed the final Work Statement NB-2 under the Clinical Trial Services Agreement and the related Stock Issuance Agreement. Pursuant to the Work Statement NB-2, Nordic will provide clinical trial services relating to the Phase 2 Clinical Study and will be compensated for such services in a combination of cash and shares of stock. Payments in cash to be made by the Company to Nordic under the Work Statement NB-2 are denominated in both euros and U.S. dollars and total up to €3.6 million ($5.0 million) and $0.3 million, respectively. In addition, the Company will issue to Nordic shares of its Series A-6 stock having a value of up to $2.9 million, as additional payment for services to be provided under the Work Statement NB-2 and the Services Agreement.
	The Stock Issuance Agreement provides that Nordic is entitled to receive quarterly stock dividends in connection with services performed under Work Statement NB-2, payable in shares of Series A-6, or shares of common stock if the Company's preferred stock has been automatically converted in accordance with its amended certificate of incorporation. In the event Nordic sells the shares of Series A-5 or in the event the shares of Series A-5 are converted into common stock in accordance with the Company's amended certificate of incorporation, this right to receive the Nordic Accruing Dividend will terminate, but a right to receive an equivalent number of shares of Series A-6 or common stock, as applicable, will remain with Nordic as a contractual right under the Stock Issuance Agreement.
	The Nordic Accruing Dividend related to the Phase 2 Clinical Study is determined based upon the estimated period that will be required to complete the Phase 2 Clinical Study. On each Accrual Date, beginning with the quarter ended December 31, 2012, the Company will recognize a liability to issue shares of Series A-6 to Nordic with an Applicable Quarterly Amount value equal to up to $2.9 million minus the aggregate value of any prior Nordic Accruing Dividend related to the Phase 2 Clinical Study divided by the number of calendar quarters it will take to complete the Phase 2 Clinical Study. The Company calculates the aggregate number of shares of Series A-6 to accrue in such calendar quarter by dividing such Applicable Quarterly Amount, by the greater of (1) the fair market value of the Company's common stock as of the applicable Accrual Date or (2) $8.142 and rounding down the resulting quotient to the nearest whole number. Such shares due to Nordic are to be issued when declared or paid by the Company's Board of Directors, who are required to do so upon Nordic's request, or upon an event of sale. As of December 31, 2013, 32,215 shares of Series A-6 were due to Nordic under Work Statement NB-2, or, after the automatic conversion into common stock of the Company's preferred stock, 322,150 shares the Company's common stock. In December 2013, Nordic requested that all shares of Series A-6 accrued as of December 31, 2013 under Work Statement NB-2 be issued. Accordingly, the Company's Board of Directors declared a dividend to Nordic of all 32,215 shares of Series A-6 accrued under Work Statement NB-2 on December 31, 2013.
	Prior to the issuance of shares of stock to Nordic in satisfaction of the Nordic Accruing Dividend, the liability to issue shares of stock was being accounted for as a liability in the Company's balance sheet, based upon the fair value of the Series A-6 as determined using PWERM. Changes in the fair value from the date of accrual to the date of issuance of the Series A-6 shares are recorded as a gain or loss in other income (expense) in the statement of operations.
	The Company recognizes research and development expense for the amounts due to Nordic under the Work Statement NB-2 ratably over the estimated per patient treatment period beginning upon enrollment in the Phase 2 Clinical Study, or a nine-month period. The Company recorded $4.1 million and $1.4 million of research and development expense during the years ended December 31, 2013 and 2012, respectively, for per patient costs incurred for patients that had enrolled in the Phase 2 Clinical Study. Additionally, the Company recorded approximately $0.9 million of research and development expense associated with the costs incurred for preparatory and other start-up costs to initiate the Phase 2 Clinical Study during the year ended December 31, 2012.
	As of December 31, 2013, the Company has a liability of $0.5 million that is reflected in accrued expenses and other current liabilities on the balance sheet resulting from services provided by Nordic, which are payable in cash.
	The Company is also responsible for certain pass-through costs in connection with the Phase 3 Clinical Study, Extension Study and Phase 2 Clinical Study. Pass through costs are expensed as incurred or upon delivery. The Company recognized research and development expense of $3.9 million, $6.0 million, and $5.0 million for pass-through costs during the years ended December 31, 2013, 2012, and 2011, respectively.

Stockbased_Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2013
Stock-based Compensation	'
Stock-based Compensation	'
	14. Stock-based Compensation
	The Company has the following stock-based compensation plans as of December 31, 2013, under which equity awards have been granted to employees, directors and consultants:
	•
	2003 Long-Term Incentive Plan; and
	•
	2011 Equity Incentive Plan.
	The 2011 Equity Incentive Plan replaced the 2003 Long-Term Incentive Plan when the board of directors approved the new plan on November 7, 2011. As of December 31, 2013, an aggregate of approximately 7,772,000 shares have been authorized for issuance under the Company's stock-based compensation plans, with approximately 3,801,000 options outstanding. The number of common shares available for granting of future awards to employees and directors under these plans was approximately 3,267,000 at December 31, 2013.
	2003 Long-Term Incentive Plan—The Company's 2003 Long-Term Incentive Plan (the "Incentive Plan") provides for the granting of incentive stock options and nonqualified options to key employees, directors and consultants of the Company. The exercise price of the incentive stock options, as determined by the board of directors, must be at least 100% (110% in the case of incentive stock options granted to a stockholder owning in excess of 10% of the Company's common stock) of the common stock fair value as of the date of the grant. The provisions of the Incentive Plan limit the exercise of incentive stock options, but in no case may the exercise period extend beyond ten years from the date of grant (five years in the case of incentive stock options granted to a stockholder owning in excess of 10% of the Company's common stock). Stock options generally vest over a four-year period. Certain options contain explicit performance conditions. The Company authorized approximately 2,016,000 shares of common stock for issuance under the Incentive Plan.
	2011 Equity Incentive Plan—The Company's 2011 Equity Incentive Plan (the "Equity Plan") provides for the granting of incentive stock options and nonqualified options to key employees, directors and consultants of the Company. The exercise price of the incentive stock options, as determined by the board of directors, must be at least 100% (110% in the case of incentive stock options granted to a stockholder owning in excess of 10% of the Company's common stock) of the common stock fair value as of the date of the grant. The provisions of the Equity Plan limit the exercise of incentive stock options, but in no case may the exercise period extend beyond ten years from the date of grant (five years in the case of incentive stock options granted to a stockholder owning in excess of 10% of the Company's common stock). Stock options generally vest over a four-year period. Certain options contain explicit performance conditions. The Company has authorized approximately 5,756,000 shares of common stock for issuance under the Equity Plan. In addition, the shares remaining available for issuance under the Incentive Plan were assumed as shares authorized under the Equity Plan.
	The Company has historically granted stock options at exercise prices no less than the fair value of its common stock as determined by its board of directors, with input from management. The Company's board of directors has historically determined, with input from management, the estimated fair value of the Company's common stock on the date of grant based on a number of objective and subjective factors, including:
	•
	the prices at which the Company sold shares of convertible preferred stock;
	•
	the superior rights and preferences of securities senior to the Company's common stock at the time of each grant;
	•
	the likelihood of achieving a liquidity event such as a public offering or sale of the Company;
	•
	the Company's historical operating and financial performance and the status of its research and product development efforts; and
	•
	achievement of enterprise milestones, including entering into collaboration and license agreements.
	The Company's board of directors also considers valuations provided by management in determining the fair value of its common stock and has consistently used the most recent valuation provided by management for determining the fair value of its common stock unless a specific event occurs that necessitates an interim valuation. The valuations utilized are prepared based on the guidance from the Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the "Practice Aid") that was developed by staff of the American Institute of Certified Public Accountants and a task force comprising representatives from the appraisal, preparer, public accounting, venture capital and academic communities and utilize PWERM, as outlined in the Practice Aid. PWERM considers the value of preferred and common stock based upon the probability-weighted present value of expected future net cash flows, considering each of the possible future events, as well as the rights and preferences of each share class. PWERM is complex as it requires numerous assumptions relating to potential future outcomes of equity, hence, the use of this method can be applied: (1) when possible future outcomes can be predicted with reasonable certainty; and (2) when there is a complex capital structure (i.e., several classes of preferred and common stock).
	During the year ended December 31, 2013, the Company granted options on November 14, 2013. The Company utilized the fair value of its common stock derived from the September 30, 2013 valuation for purposes of the November 14, 2013 option grant and concluded that for purposes of the November 14, 2013 grant, there were no significant changes to the assumptions used in the PWERM model between November 14, 2013 and September 30, 2013 that would impact the fair value of our common stock. The Company also used this methodology to estimate the fair value of its preferred stock.
	The Company uses the Black-Scholes option-pricing model to estimate the grant date fair value of its employee stock options. The weighted-average assumptions used in the Black-Scholes option-pricing model and the resulting weighted- average estimated grant date fair values of its employee stock options were as follows for the years ended December 31, 2013, 2012, and 2011:
		Year Ended December 31,
		2013			2012			2011
	Expected term (years)		6.25			6.25			6.25
	Volatility		62	%		60	%		60	%
	Expected dividend yield		0	%		0	%		0	%
	Risk-free interest rates		2.45	%		1.1	%		1.35	%
	A summary of stock option activity for the year ended December 31, 2013 is as follows:
		Shares			Weighted-Average			Weighted-Average			Aggregate
					Exercise Price			Contractual			Intrinsic
					(in dollars			Life			Value
					per share)			(In Years)
	Options outstanding at December 31, 2012		3,899		$	3.1
	Granted		2,427			3.45
	Exercised		(12	)		1.1
	Forfeited		(2,502	)		3.47
	Expired		(11	)		1.5
	Options outstanding at December 31, 2013		3,801		$	3.09			7.07		$	2,283
	Options exercisable at December 31, 2013		2,475		$	2.73			6.6		$	2,231
	Options vested or expected to vest at December 31, 2012		3,727		$	3.08			7.06		$	2,280
	The weighted-average grant-date fair value per share of options granted during 2013, 2012 and 2011 was $2.05, $2.36 and $2.07, respectively. The total grant-date fair value of stock options that vested during the years ended December 31, 2013 and 2012 was approximately $1.8 million and $1.5 million, respectively. The aggregate intrinsic value of options exercised (i.e., the difference between the market price at exercise and the price paid by employees to exercise the option) during the years ended December 31, 2013 and 2012 was $0.02 million and $0.9 million, respectively.
	The following table summarizes stock-based compensation expense by financial statement line (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Research and development	$	302		$	338		$	118
	General and administrative		1,206			1,457			186
	Share-based compensation expense included in operating expenses	$	1,508		$	1,795		$	304
	As of December 31, 2013, there was approximately $2.6 million of total unrecognized compensation expense related to unvested share-based compensation arrangements, which is expected to be recognized over a weighted- average period of approximately two years.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2013
Net Loss Per Share	'
Net Loss Per Share	'
	15. Net Loss Per Share
	Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts):
		Year Ended December 31,
		2013			2012			2011
	Numerator:
	Net loss	$	(60,690	)	$	(69,128	)	$	(42,476	)
	Extinguishment of preferred stock		—			—			60,937
	Accretion of preferred stock		(17,471	)		(13,992	)		(10,933	)
	Earnings attributable to participating preferred stockholders		—			—			(7,275	)
	Earnings (loss) attributable to common stockholders—basic		(78,161	)		(83,120	)		253
	Effect of dilutive convertible preferred stock		—			—			—
	Earnings (loss) attributable to common stockholders—diluted	$	(78,161	)	$	(83,120	)	$	253
	Denominator:
	Weighted-average number of common shares used in (loss) earnings per share—basic		874,004			839,698			499,944
	Effect of dilutive options to purchase common stock		—			—			464,933
	Effect of dilutive convertible preferred stock		—			—			2,489,399
	Weighted-average number of common shares used in (loss) earnings per share—diluted		874,004			839,698			3,454,276
	(Loss) earnings per share—basic	$	(89.43	)	$	(98.99	)	$	0.51
	Effect of dilutive options to purchase common stock		—			—		$	(0.24	)
	Effect of dilutive convertible preferred stock		—			—		$	(0.20	)
	(Loss) earnings per share—diluted	$	(89.43	)	$	(98.99	)	$	0.07
	The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive. For the years ended December 31, 2013 and 2012, all convertible preferred stock, options to purchase common stock and warrants outstanding were assumed to be anti-dilutive as earnings attributable to common stockholders was in a loss position.
		Year Ended December 31
		2013			2012			2011
	Convertible preferred stock		11,315,006			4,834,687			5,419,946
	Options to purchase common stock		3,976,072			3,890,911			894,160
	Warrants		1,225,221			15,000			8,860

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Income Taxes	'
	16. Income Taxes
	As of December 31, 2013 the Company had federal and state net operating loss ("NOL") carryforwards of approximately $263.6 million and $229.4 million, respectively, which may be used to offset future taxable income. The Company also had federal and state tax credits of $4.0 million and $0.5 million, respectively, to offset future tax liabilities. The NOL and tax credit carryforwards will expire at various dates through 2033, and are subject to review and possible adjustment by federal and state tax authorities. The Internal Revenue Code contains provision that may limit the NOL and tax credit carryforwards available to be used in any given year in the event of certain changes in the ownership interests of significant stockholders under Section 382 of the Internal Revenue Code.
	A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows (in thousands):
		Year Ended December 31,
		2013			2012			2011
	Income tax benefit using U.S. federal statutory rate	$	(20,635	)	$	(23,504	)	$	(14,509	)
	State income taxes, net of federal benefit		(2,255	)		(2,774	)		(1,854	)
	Stock-based compensation		92			72			49
	Research and development tax credits		(1,277	)		(55	)		(385	)
	Change in the valuation allowance		27,194			25,175			17,041
	Permanent items		(3,085	)		709			91
	Other		(34	)		377			(433	)
		$	—		$	—		$	—
	The Company is subject to Massachusetts net worth taxes, not based on income, which is largely offset by allowable tax credits and recorded as a component of operating expenses.
	The principal components of the Company's deferred tax assets are as follows (in thousands):
		December 31,
		2013			2012
	Current assets:
	Accrued expenses	$	351		$	343
	Deferred Rent		9			—
	Gross current deferred tax assets		360			343
	Valuation allowance		(360	)		(343	)
	Net current deferred tax assets	$	—		$	—
	Non-current assets:
	Net operating loss carryforwards	$	100,284		$	74,487
	Capitalized research and development		662			1,042
	Research and development credits		4,345			3,067
	Depreciation and amortization		110			90
	Other		1,313			851
	Gross non-current deferred tax assets		106,714			79,537
	Valuation allowance		(106,714	)		(79,537	)
	Net non-current deferred tax assets	$	—		$	—
	The Company has recorded a valuation allowance against its deferred tax assets in each of the years ended December 31, 2013 and 2012, because the Company's management believes that it is more likely than not that these assets will not be realized. The increase in the valuation allowance in 2013 primarily relates to the net loss incurred by the Company.
	As of December 31, 2013, the Company has no unrecognized tax benefits or related interest and penalties accrued. The Company has not, as yet, conducted a study of research and development ("R&D") credit carryforwards. In addition, the Company has not, as yet, conducted an Internal Revenue Code Section 382 study, which could impact its ability to utilize available NOL and tax credit carryforwards. These studies may result in adjustments to the Company's R&D credit carryforwards and NOL carryfowards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company's R&D credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet or statement of operations if an adjustment were required. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company has not recorded any interest or penalties on any unrecognized benefits since inception.
	The statute of limitations for assessment by the Internal Revenue Service ("IRS") and state tax authorities remains open for all tax years. The Company files income tax returns in the United States and Massachusetts. There are currently no federal or state audits in progress.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies	'
Commitments and Contingencies	'
	17. Commitments and Contingencies
	Litigation—The Company may be exposed to certain claims or assessments in the ordinary course of business. In the opinion of management, the outcome of these matters is not likely to have any material effect on the financial position, results of operations, or cash flows of the Company.
	Commitments—On January 14, 2011, the Company signed a sublease agreement for office space in Cambridge, Massachusetts that expired on July 31, 2011. Monthly rental payments under this sublease were $9.0 thousand and the Company moved into the space in February 2011. On July 15, 2011, the Company entered into an operating lease agreement to remain in the same Cambridge, Massachusetts location. The term of the lease is August 1, 2011 through July 31, 2014. Monthly rental payments under the new lease are approximately $15.0 thousand for the first 12 months and approximately $16.0 thousand for the 24 months thereafter.
	Rent expense for the years ended December 31, 2013, 2012 and 2011 was $0.2 million, $0.2 million and $0.1 million, respectively.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions	'
Related Party Transactions	'
	18. Related Party Transactions
	On July 24, 2013, the Company entered into a Consulting Agreement with Morana Jovan-Embiricos, Ph.D. (the "Consulting Agreement"), a member of the Company's board of directors. Pursuant to the Consulting Agreement, Dr. Jovan-Embiricos agreed to provide financial and strategic consulting services as may be requested by the Company, and such other consulting services as may be reasonably requested by the Company, from time to time from July 1, 2013 until June 30, 2014. The Company agreed to pay Dr. Jovan-Embiricos an aggregate consulting fee in cash of $160,000, of which $80,000 was paid on July 30, 2013 and the remaining $80,000 was paid on October 2, 2013.
	On January 23, 2014, the Company entered into a consulting agreement with Orbit Advisors Limited (the "Orbit Agreement"), a Swiss company ("Orbit"), and Morana Jovan-Embiricos, Ph.D and an agreement terminating the Consulting Agreement dated July 24, 2013. The Orbit Agreement is effective as of January 22, 2014 and will continue in effect until December 31, 2014 or until the earlier termination thereof in accordance with its terms (the "Term"). Pursuant to the Orbit Agreement, Orbit has agreed to provide financial and strategic consulting services as may be requested by the Company, and such other consulting services as may be reasonably requested by the Company, from time to time during the Term. The Company agreed to pay Orbit an aggregate consulting fee in cash of $400,000 in four equal installments of $100,000 on each of January 31, 2014, June 30, 2014, September 30, 2014 and December 31, 2014. The Orbit Agreement contains customary provisions, applicable to both Orbit and Dr. Jovan-Embiricos, as Orbit's representative under the Orbit Agreement, regarding the treatment of the Company's confidential information and assignment of inventions, as well as an obligation of Orbit and Dr. Jovan-Embiricos to not solicit, during the Term and for a period of one year thereafter, any person or entity engaged by the Company as an employee, customer or supplier of, or consultant or advisor to, the Company to terminate such party's relationship with the Company.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events	'
Subsequent Events	'
	19. Subsequent Events
	Preferred Stock Offering—On February 14, 2014, the Company entered into the Series B-2 Purchase Agreement, pursuant to which the Company may raise up to approximately $40.2 million through the issuance of (1) up to 655,000 Series B-2 Shares, par value $.0001 per share, and (2) warrants to acquire up to 1,637,500 shares of its common stock, at an exercise price of $6.142 per share.
	Shares of the Company's Series B-2 convertible preferred stock (the "Series B-2") are convertible, in whole or in part, at the option of the holder at any time into shares of common stock, on a ten-for-one basis at an initial effective conversion price of $6.142 per share. Holders of shares of Series B-2 are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series B-2. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, including upon mandatory conversion of the Series B upon the Company's common stock becoming listed for trading on a national stock exchange. The holders of shares of Series B-2 are also entitled to dividends declared or paid on any shares of common stock.
	The Series B-2 Shares rank senior in payment to any other dividends payable on any and all series of preferred stock and upon liquidation, or an event of sale, each share of Series B-2 shall rank equally with each other share of Series B-2 and New Series B, senior to all shares of Series A-1, Series A-2, Series A-3, Series A-4, Series A-5 and Series A-6 and senior to all shares of common stock. In the event of a liquidation, dissolution, or winding-up of the Company, the holders of the Series B-2 are entitled to be paid first out of the assets available for distribution, before any payment is made to the Series A-1, Series A-2, Series A-3, Series A-4, Series A-5 and Series A-6. Payment in respect of a liquidation, or event of sale, to the holders of Series B shall consist of one and a half time (1.5) times the original issuance price of $61.42, plus all accrued but unpaid dividends.
	On February 14, 2014, February 19, 2014 and February 24, 2014, the Company consummated closings under the Series B-2 Purchase Agreement, whereby, in exchange for aggregate proceeds to the Company of approximately $25.6 million, the Company issued an aggregate of 417,615 Series B-2 Shares and warrants to purchase up to a total of 1,044,039 shares of our common stock.
	Each share of Series B-2 has the right to that number of votes per share as is equal to the number shares of common stock into which such share of Series B-2 is then convertible.
	The warrants issuable pursuant to the Purchase Agreement are exercisable at any time prior to the fifth anniversary of their issuance.
	The issuance on February 14, 2014, February 19, 2014 and February 24, 2014, of the Series B-2 and accompanying warrants under the Purchase Agreement resulted in an additional adjustment to the Conversion Price of the Series A-1, Series A-2 and Series A-3. As a result of the Anti-Dilution Adjustment, the effective conversion price of each share of Series A-1, Series A-2 and Series A-3 was reduced from $7.627 to $7.464. Accordingly, each share of Series A-1, Series A-2 and Series A-3 is currently convertible into 10.908 shares of common stock.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies	'
Use of Estimates	'
	Use of Estimates—The preparation of financial statements in conformity with accounting principles generally accepted in the United States ("GAAP") requires the Company's management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued as additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated up to the date of issuance of these financial statements.
Cash Equivalents	'
	Cash Equivalents—The Company considers all highly liquid investment instruments with an original maturity when purchased of three months or less to be cash equivalents. Cash equivalents at December 31, 2013 and December 31, 2012 are primarily comprised of money market funds.
Marketable Securities	'
	Marketable Securities—All investment instruments with an original maturity date, when purchased, in excess of three months have been classified as current marketable securities. These marketable securities are classified as available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are included within other comprehensive (loss) income within stockholders' deficit. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Realized gains and losses on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific identification method. The Company periodically reviews the portfolio of securities to determine whether an other-than-temporary impairment has occurred. No such losses have occurred to date. There were no realized gains or losses on the sale of securities for the years ended December 31, 2013 and 2012.
Fair Value Measurements	'
	Fair Value Measurements—The Company determines the fair market values of its financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following are three levels of inputs that may be used to measure fair value:
	Level 1	Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2	Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Concentrations of Credit Risk and Off-Balance-Sheet Risk	'
	Concentrations of Credit Risk and Off-Balance-Sheet Risk—Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale marketable securities. The Company mitigates its risk with respect to cash and cash equivalents and marketable securities by maintaining its deposits and investments at high-quality financial institutions. The Company invests any excess cash in money market funds and other securities, and the management of these investments is not discretionary on the part of the financial institution. The Company's credit exposure on its marketable securities is limited by its diversification among United States government and agency debt securities. The Company has no significant off-balance-sheet risks such as foreign exchange contracts, option contracts, or other hedging arrangements.
Property and Equipment	'
	Property and Equipment—Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets.
Research and Development Costs	'
	Research and Development Costs—The Company accounts for research and development costs by expensing such costs to operations as incurred. Research and development costs primarily consist of clinical testing costs, including payments in cash and stock made to contracted research organizations, personnel costs, outsourced research activities, laboratory supplies, and license fees.
	Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
Licensing Agreements	'
	Licensing Agreements—Costs associated with licenses of technology are expensed as incurred, and are included in research and development expenses.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets—The Company evaluates long-lived assets for potential impairment when there is evidence that events or changes in circumstances have occurred that indicate that the carrying amount of a long-lived asset may not be recovered. Recoverability of these assets is assessed based on the undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends, and product development cycles. Impairment in the carrying value of each asset is assessed when the undiscounted expected future cash flows derived from the asset are less than its carrying value.
	An impairment loss would be recognized in an amount equal to the excess of the carrying amount over the undiscounted expected future cash flows. No impairment charges have been recognized since the Company's inception.
Segment Information	'
	Segment Information—Operating segments are defined as components of an enterprise engaged in business activities for which discrete financial information is available and regularly reviewed by the chief decision maker in determining how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating segment and operates in one geographic area.
Income Taxes	'
	Income Taxes—The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as operating loss and tax credit carry forwards. The Company measures deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization. The effect on deferred tax assets and liabilities as a result of a change in tax rates is recognized as income in the period that includes the enactment date.
	The Company uses judgment to determine the recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Any material interest and penalties related to unrecognized tax benefits are recognized in income tax expense.
	Due to uncertainty surrounding the realization of the favorable tax attributes in future tax returns the Company has recorded a full valuation allowance against otherwise realizable net deferred tax assets as of December 31, 2013 and 2012.
Financial Instruments Indexed to and Potentially Settled in the Company's Common Stock	'
	Financial Instruments Indexed to and Potentially Settled in the Company's Common Stock —The Company evaluates all financial instruments issued in connection with its equity offerings when determining the proper accounting treatment for such instruments in the Company's financial statements. The Company considers a number of generally accepted accounting principles to determine such treatment and evaluates the features of the instrument to determine the appropriate accounting treatment. The Company utilizes the Black-Scholes method or other appropriate methods to determine the fair value of its derivative financial instruments. Key valuation factors in determining the fair value include, but are not limited to, the current stock price as of the date of measurement, the exercise price, the remaining contractual life, expected volatility for the instrument and the risk-free interest rate. For financial instruments that are determined to be classified as liabilities on the balance sheet, changes in fair value are recorded as a gain or loss in the Company's statement of operations, with the corresponding amount recorded as an adjustment to the liability on its balance sheet.
Stock-Based Compensation	'
	Stock-Based Compensation—The Company measures stock-based compensation cost at the accounting measurement date based on the fair value of the option, and recognizes the expense on a straight-line basis over the requisite service period of the option, which is typically the vesting period. The Company estimates the fair value of each option using a Black-Scholes option pricing model that takes into account the fair value of its common stock, the exercise price, the expected life of the option, the expected volatility of the Company's common stock, expected dividends on the Company's common stock, and the risk-free interest rate over the expected life of the option. Due to its limited history, the Company uses the simplified method described in the SEC's Staff Accounting Bulletin No. 107, Share-Based Payment, to determine the expected life of the option grants. The Company's estimate of expected volatility is based on a review of the historical volatility of similar publicly held companies in the biotechnology field over a period commensurate with the option's expected term. The Company has never declared or paid any cash dividends on its common stock and does not expect to do so in the foreseeable future. Accordingly, the Company utilizes an expected dividend yield of zero. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant valuation for a period commensurate with the option's expected term. These assumptions are highly subjective and changes in them could significantly impact the value of the option and hence the related compensation expense.
	The Company applies an estimated forfeiture rate to current period expense to recognize compensation expense only for those awards expected to vest. Estimated forfeitures are based upon historical data, adjusted for known trends, and will be adjusted if actual forfeitures differ or are expected to differ from such estimates. Subsequent changes in estimated forfeitures are recognized through a cumulative adjustment in the period of change and also will impact the amount of stock-based compensation expense in future periods.
	Stock-based compensation expense for options granted to consultants is also determined based upon the fair value of the options issued, as determined by the Black-Scholes option pricing model. However, the unvested portion of such option grants is re-measured at each reporting period, until such time as the award is fully vested.
Net (Loss) Income Per Common Share	'
	Net (Loss) Income Per Common Share—Net (loss) income per common share is calculated using the two-class method, which is an earnings allocation formula that determines net (loss) income per share for the holders of the Company's common shares and participating securities. All of the Company's series of preferred stock contain participation rights in any dividend paid by the Company and are deemed to be participating securities. Net income available to common shareholders and participating preferred shares is allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss.
	Diluted net income per share is computed using the more dilutive of (a) the two-class method, or (b) the if-converted method. The Company allocates net income first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares outstanding gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, and potential issuance of stock upon the issuance of the Company's series A-6 convertible preferred stock ("Series A-6") as settlement of the liability to Nordic Bioscience ("Nordic"). Common equivalent shares are excluded from the computation of diluted net income per share if their effect is anti-dilutive.
Comprehensive (Loss) Income	'
	Comprehensive (Loss) Income—Comprehensive (loss) income refers to revenues, expenses, gains and losses that are excluded from net income, as these amounts are recorded directly as an adjustment to stockholders' deficit, net of tax. The Company's other comprehensive (loss) income is comprised of unrealized gains (losses) on its available-for-sale securities.
New Accounting Pronouncements	'
	Accounting Standards Updates—In July 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists ("ASU 2013-11"). ASU 2013-11 clarifies guidance and eliminates diversity in practice on the presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments under ASU 2013-11 are effective for interim and annual fiscal periods beginning after December 15, 2013, with early adoption permitted. The Company does not expect adoption of ASU 2013-11 will have a material impact on its results of operations, financial position, or cash flows.
	In December 2013, the FASB issued Accounting Standards Update No. 2013-12, Definition of a Public Business Entity ("ASU 2013-12"). ASU 2013-12 amends the Master Glossary of the FASB Accounting Standards Codification to include one definition of public business entity for future use in GAAP. ASU 2013-12 does not affect existing requirements but will be used in considering the scope of new financial guidance and will identify whether the guidance does or does not apply to public business entities. There is no actual effective date for the amendment in ASU 2013-12 and the Company does not expect ASU 2013-12 will have a material impact on its results of operations, financial position or cash flows.
	Recently Adopted Accounting Standards—In February 2013, FASB issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income ("ASU 2013-02"). Under ASU 2013-02, an entity is required to provide information about amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income, but only if the amount reclassified is required to be reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. ASU 2013-02 does not change the current requirements for reporting net income or other comprehensive income in the financial statements. The Company adopted ASU 2013-02 on January 1, 2013. Its adoption did not have a material impact on the Company's results of operations, financial position or cash flows.

Recapitalization_Tables

Recapitalization (Tables)	12 Months Ended
	Dec. 31, 2013
Recapitalization	'
Schedule of outstanding preferred stock	'
	Class	Number
		of Shares
	Series A-1		939,612
	Series A-2		983,208
	Series A-3		142,227
	Series A-4		3,998
	Series A-5		6,443

Marketable_Securities_Tables

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2013
Marketable Securities	'
Schedule of available-for-sale marketable securities and cash and cash equivalents	'
	Available-for-sale marketable securities and cash and cash equivalents consist of the following (in thousands):
		December 31, 2013
		Amortized		Gross		Gross		Fair Value
		Value		Unrealized		Unrealized
				Gains		Losses
	Cash and cash equivalents:
	Cash	$	2,710	$	—	$	—	$	2,710
	Money market		9,593		—		—		9,593
	Total	$	12,303	$	—	$	—	$	12,303
		December 31, 2012
		Amortized		Gross		Gross		Fair Value
		Cost		Unrealized		Unrealized
		Value		Gains		Losses
	Cash and cash equivalents:
	Cash	$	1,134	$	—	$	—	$	1,134
	Money market		16,020		—		—		16,020
	Domestic corporate commercial paper		1,499		—		—		1,499
	Total	$	18,653	$	—	$	—	$	18,653
	Marketable securities:
	Domestic corporate commercial paper		4,000		—		—		4,000
	Total	$	4,000	$	—	$	—	$	4,000

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property and Equipment	'
Schedule of property and equipment	'
	Property and equipment consists of the following (in thousands):
			December 31,
		Estimated Useful Life
		(In Years)	2013			2012
	Furniture and fixtures	5	$	68		$	68
	Computer equipment and software	3		286			284
	Leasehold improvements	Shorter of useful life or remaining lease term		505			505
				859			857
	Less accumulated depreciation and amortization			(783	)		(718	)
	Property and equipment, net		$	76		$	139

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities	'
Schedule of accrued expenses	'
	Accrued expenses consist of the following (in thousands):
		December 31,
		2013		2012
	Research costs	$	19,597	$	6,558
	Payroll and employee benefits		1,005		962
	Professional fees		426		399
	Vacation		69		129
	Accrued interest on notes payable		852		595
	Other		58		97
	Total accrued expenses and other current liabilties	$	22,007	$	8,740

Loan_and_Security_Agreement_Ta

Loan and Security Agreement (Tables)	12 Months Ended
	Dec. 31, 2013
Loan and Security Agreement	'
Schedule of future principal payments under Loan and Security Agreement	'
	Future principal payments under the Loan and Security Agreement at December 31, 2013, are as follows (in thousands):
		Principal
		Payments
	Current portion of net payable		13,156
	Discount on current portion of note payable		(151	)
	Current portion of net payable, net of discount	$	13,005

Stockholders_Deficit_Tables

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Deficit	'
Schedule of number of shares of common stock reserved	'
	The Company has reserved the following number of shares of common stock (in thousands):
		December 31,
		2013		2012
	Conversion of New Series B Preferred Stock		9,800		—
	Conversion of Series A-1 Preferred Stock		10,000		10,000
	Conversion of Series A-2 Preferred Stock		9,832		9,832
	Conversion of Series A-3 Preferred Stock		1,422		1,422
	Conversion of Series A-4 Preferred Stock		40		40
	Conversion of Series A-5 Preferred Stock		70		70
	Conversion of Series A-6 Preferred Stock		8,000		8,000
	Stock options and Warrants		18,842		19,656
	Total		58,006		49,020

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Measurements	'
Summary of financial assets and liabilities measured at fair value on a recurring basis	'
	The following tables summarize the financial assets and liabilities measured at fair value on a recurring basis in the accompanying balance sheets as of December 31, 2013 and 2012 (in thousands):
		As of December 31, 2013
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash	$	2,710		$	—	$	—	$	2,710
	Money market funds(1)		9,593			—		—		9,593
		$	12,303		$	—	$	—	$	12,303
	Liabilities
	Warrant liability(2)	$	—		$	—	$	1,945	$	1,945
	Stock Liability(2)						$	5,328	$	5,328
		$	—		$	—	$	7,273	$	7,273
		As of December 31, 2012
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash	$	1,134		$	—	$	—	$	1,134
	Money market funds(1)		16,020			—		—		16,020
	Domestic corporate commercial paper(3)		—			1,499		—		1,499
	Marketable Securities:
	Domestic corporate commercial paper(3)		—			4,000		—		4,000
	Stock asset(2)		—			—		407		407
		$	17,154		$	5,499	$	407	$	23,060
	Liabilities
	Warrant liability(2)	$	—		$	—	$	830	$	830
	Other liability(2)		—			—		24,387		24,387
	Stock liability(2)							245		245
		$	—		$	—	$	25,462	$	25,462
	-1
	Fair value is based upon quoted market prices.
	-2
	Fair value is determined using the probability-weighted expected return model ("PWERM"), as discussed below. Changes in the fair value of the Level 3 assets and liabilities are recorded as other (expense) income in the statement of operations.
	-3
	Fair value is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources, including market participants, dealers and brokers.
Schedule of quantitative information about the Company's Level 3 fair value measurements, including significant unobservable inputs	'
	Instrument	Valuation		Unobservable Input		Estimate
		Technique
	Preferred Stock	PWERM		•		•
				Time until future exit event (years)		0.0 - 0.4
				•		•
				Probability of abaloparatide coming to market		65% - 75%
				•		•
				Discount rate		20% - 40%
				•		•
				Long-term revenue growth rate(1)		2% - 117%
				•		•
				Long-term pre-tax operating margin(2)		13% - 79%
				•		•
				Discount for lack of marketability		10% - 36%
		Market Comparable Companies		•		•
				Revenue multiple(3)		3.2 - 8.0
	-1
	Estimated long-term revenue growth rate has the above range and an average of approximately 27% over 16 revenue years.
	-2
	Estimated long-term pretax operating margin has the above range after achieving positive pretax operating margin and an average of approximately 68% for 17 years.
	-3
	Represents amounts used when the Company has determined that market participants would use such multiples when valuing the Company's preferred stock.
Roll-forward of fair value of assets determined by Level 3 inputs	'
	The following table provides a roll forward of the fair value of the assets, where fair value is determined using Level 3 inputs (in thousands):
	Balance at January 1, 2012	$	3,379
	Expense recognized		(4,080	)
	Additions		398
	Change in fair value		710
	Balance at December 31, 2012	$	407
	Expense recognized		(313	)
	Additions		86
	Change in fair value		(180	)
	Balance at December 31, 2013	$	—
Roll-forward of fair value of liabilities determined by Level 3 inputs	'
	The following table provides a roll forward of the fair value of the liabilities, where fair value is determined using Level 3 inputs (in thousands):
	Balance at January 1, 2012	$	10,920
	Additions		11,763
	Change in fair value		2,779
	Balance at December 31, 2012	$	25,462
	Issuance of shares of Series A-6		(23,168	)
	Additions		14,246
	Change in fair value		(9,267	)
	Balance at December 31, 2013	$	7,273

Stockbased_Compensation_Tables

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Stock-based Compensation	'
Schedule of weighted-average assumptions used in estimation of grant date fair values	'
		Year Ended December 31,
		2013			2012			2011
	Expected term (years)		6.25			6.25			6.25
	Volatility		62	%		60	%		60	%
	Expected dividend yield		0	%		0	%		0	%
	Risk-free interest rates		2.45	%		1.1	%		1.35	%
Summary of stock option activity	'
		Shares			Weighted-Average			Weighted-Average			Aggregate
					Exercise Price			Contractual			Intrinsic
					(in dollars			Life			Value
					per share)			(In Years)
	Options outstanding at December 31, 2012		3,899		$	3.1
	Granted		2,427			3.45
	Exercised		(12	)		1.1
	Forfeited		(2,502	)		3.47
	Expired		(11	)		1.5
	Options outstanding at December 31, 2013		3,801		$	3.09			7.07		$	2,283
	Options exercisable at December 31, 2013		2,475		$	2.73			6.6		$	2,231
	Options vested or expected to vest at December 31, 2012		3,727		$	3.08			7.06		$	2,280
Summary of stock-based compensation expense by financial statement line	'
	The following table summarizes stock-based compensation expense by financial statement line (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Research and development	$	302		$	338		$	118
	General and administrative		1,206			1,457			186
	Share-based compensation expense included in operating expenses	$	1,508		$	1,795		$	304

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Net Loss Per Share	'
Schedule of basic and diluted net loss per share	'
	Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts):
		Year Ended December 31,
		2013			2012			2011
	Numerator:
	Net loss	$	(60,690	)	$	(69,128	)	$	(42,476	)
	Extinguishment of preferred stock		—			—			60,937
	Accretion of preferred stock		(17,471	)		(13,992	)		(10,933	)
	Earnings attributable to participating preferred stockholders		—			—			(7,275	)
	Earnings (loss) attributable to common stockholders—basic		(78,161	)		(83,120	)		253
	Effect of dilutive convertible preferred stock		—			—			—
	Earnings (loss) attributable to common stockholders—diluted	$	(78,161	)	$	(83,120	)	$	253
	Denominator:
	Weighted-average number of common shares used in (loss) earnings per share—basic		874,004			839,698			499,944
	Effect of dilutive options to purchase common stock		—			—			464,933
	Effect of dilutive convertible preferred stock		—			—			2,489,399
	Weighted-average number of common shares used in (loss) earnings per share—diluted		874,004			839,698			3,454,276
	(Loss) earnings per share—basic	$	(89.43	)	$	(98.99	)	$	0.51
	Effect of dilutive options to purchase common stock		—			—		$	(0.24	)
	Effect of dilutive convertible preferred stock		—			—		$	(0.20	)
	(Loss) earnings per share—diluted	$	(89.43	)	$	(98.99	)	$	0.07
Schedule of potentially dilutive securities excluded from the computation of diluted weighted-average shares outstanding	'
		Year Ended December 31
		2013			2012			2011
	Convertible preferred stock		11,315,006			4,834,687			5,419,946
	Options to purchase common stock		3,976,072			3,890,911			894,160
	Warrants		1,225,221			15,000			8,860

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Schedule of reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations	'
	A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows (in thousands):
		Year Ended December 31,
		2013			2012			2011
	Income tax benefit using U.S. federal statutory rate	$	(20,635	)	$	(23,504	)	$	(14,509	)
	State income taxes, net of federal benefit		(2,255	)		(2,774	)		(1,854	)
	Stock-based compensation		92			72			49
	Research and development tax credits		(1,277	)		(55	)		(385	)
	Change in the valuation allowance		27,194			25,175			17,041
	Permanent items		(3,085	)		709			91
	Other		(34	)		377			(433	)
		$	—		$	—		$	—
Schedule of principal components of the Company's deferred tax assets	'
	The principal components of the Company's deferred tax assets are as follows (in thousands):
		December 31,
		2013			2012
	Current assets:
	Accrued expenses	$	351		$	343
	Deferred Rent		9			—
	Gross current deferred tax assets		360			343
	Valuation allowance		(360	)		(343	)
	Net current deferred tax assets	$	—		$	—
	Non-current assets:
	Net operating loss carryforwards	$	100,284		$	74,487
	Capitalized research and development		662			1,042
	Research and development credits		4,345			3,067
	Depreciation and amortization		110			90
	Other		1,313			851
	Gross non-current deferred tax assets		106,714			79,537
	Valuation allowance		(106,714	)		(79,537	)
	Net non-current deferred tax assets	$	—		$	—

Nature_of_Business_Details

Nature of Business (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Feb. 24, 2014	Feb. 14, 2014	Feb. 14, 2014	Feb. 24, 2014	Feb. 14, 2014
			Series B-2 Purchase Agreement	Series B-2 Purchase Agreement	Series B-2 Purchase Agreement	Series B-2 Purchase Agreement	Series B-2 Purchase Agreement
			Subsequent Event	Subsequent Event	Maximum	Series B-2 Shares	Series B-2 Shares
					Subsequent Event	Subsequent Event	Maximum
							Subsequent Event
Nature of Business	'	'	'	'	'	'	'
Accumulated deficit	$277,301,000	$200,661,000	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Amount to be raised	'	'	'	'	40,200,000	'	'
Preferred Stock, shares authorized	'	'	'	'	'	'	655,000
Warrants that may be issued for purchase of shares of common stock (in shares)	'	'	'	'	1,637,500	'	'
Exercise price of warrants (in dollars per unit)	'	'	'	$6.14	'	'	'
Proceeds from issuance of shares	'	'	$25,600,000	'	'	'	'
Number of shares issued	'	'	'	'	'	417,615	'
Warrants issued for purchase of shares of common stock (in shares)	'	'	1,044,039	'	'	'	'

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
	item
Summary of Significant Accounting Policies	'	'
Number of operating segment	1	'
Number of geographic segment	1	'
Marketable Securities	'	'
Other-than-temporary impairment losses	$0	'
Realized gains or losses on the sale of securities	0	0
Impairment of Long-Lived Assets	'	'
Impairment charges	$0	'
Stock-Based Compensation	'	'
Expected dividend yield (as a percent)	0.00%	'

Merger_Details

Merger (Details) (USD $)	12 Months Ended					0 Months Ended
	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	17-May-11	17-May-11	17-May-11	Apr. 25, 2011	Apr. 25, 2011
				Series A-1 Convertible Preferred Stock	Series A-1 Convertible Preferred Stock	Former operating company	Former operating company	Former operating company	Former operating company	Former operating company
							Common Stock	Preferred Stock	Series A-1 Convertible Preferred Stock	Series A-1 Convertible Preferred Stock
									item	Maximum
Merger	'	'	'	'	'	'	'	'	'	'
Reverse stock-split ratio	'	'	'	'	'	0.0667	'	'	'	'
Common stock par value (in dollars per share)	$0.00	'	$0.00	'	'	$0.01	$0.00	'	'	'
Preferred stock par value (in dollars per share)	'	'	'	$0.00	$0.00	$0.01	'	$0.00	$0.00	'
Conversion ratio of stock	'	'	'	'	'	'	1	0.1	'	'
Stock repurchased (in shares)	'	'	'	'	'	5,000,000	'	'	'	'
Stock repurchased (in dollars)	'	'	'	'	'	$50,000	'	'	'	'
Percentage of ownership upon completion of the Merger and the Redemption	'	'	'	'	'	100.00%	'	'	'	'
Preferred stock obliged to be issued (in shares)	'	'	'	'	'	'	'	'	'	789,553
Purchase price per share of convertible preferred stock (in dollars per share)	'	'	'	'	'	'	'	'	$81.42	'
Number of tranches in which preferred stock is issued	'	'	'	'	'	'	'	'	3	'
Proceeds from issuance of preferred stock	$42,870,000	$62,116,000	'	'	'	'	'	'	$64,300,000	'

Recapitalization_Details

Recapitalization (Details) (USD $)

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2013

17-May-11

Dec. 31, 2013

Dec. 14, 2011

Dec. 31, 2011

17-May-11

Dec. 14, 2011

17-May-11

Nov. 18, 2011

17-May-11

Dec. 31, 2013

Dec. 31, 2013

Dec. 14, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

17-May-11

17-May-11

17-May-11

17-May-11

17-May-11

17-May-11

17-May-11

17-May-11

17-May-11

17-May-11

17-May-11

Series A-1 financing

Series A-1 financing

Series A-1 financing

Series A-1 financing

Series A-1

Series A-1

Series A-1

Series A-1

Series A-1

Series A-1

Series A-1

Series A-1

Series A-1

Series A-2

Series A-3

Series A-4

Series A-5

Additional paid-in-capital

Accumulated Deficit

Series A Convertible Preferred Stock

Series C Convertible Preferred Stock

Forced Conversion

Forced Conversion

Forced Conversion

Forced Conversion

Forced Conversion

Recapitalization

Recapitalization

Recapitalization

Recapitalization

Recapitalization

Recapitalization

Former operating company

Former operating company

Former operating company

Former operating company

Series A-1 financing

Series A-1 financing

Series A-1 financing

Series A-1 financing

Series A-1 financing

Series A-1 financing

Series A-1 financing

Common Stock

Series A Convertible Preferred Stock

Series B Convertible Preferred Stock

Series C Convertible Preferred Stock

Series A Convertible Preferred Stock

Series A Convertible Preferred Stock

Series B Convertible Preferred Stock

Series B Convertible Preferred Stock

Series C Convertible Preferred Stock

Series C Convertible Preferred Stock

Stage II and Stage III

Stage II and Stage III

Stage III

Stage I

Stage II

Former operating company

Former operating company

Former operating company

Former operating company

Series A-4

Series A-3

Series A-2

Stage II and Stage III

Stage II and Stage III

Recapitalization

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock conversion ratio (in shares)

'

'

'

'

'

'

'

'

0.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.2

'

'

'

'

'

'

'

'

'

'

Number of shares converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,661

177,697

314,496

40,003

'

1,422,300

'

9,832,133

'

Number of shares issued upon conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

102,767

'

'

'

'

40,003

'

1,422,300

'

9,832,133

Additional shares issued in exchange for additional investment

'

'

'

'

'

'

'

'

'

'

'

'

1,327,506

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from issuance of preferred stock (in dollars)

$42,870,000

$62,116,000

'

'

'

'

'

'

'

$21,000,000

$20,300,000

$21,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued

'

'

'

'

'

'

'

939,612

'

263,180

2,631,845

263,178

'

'

'

'

983,208

142,227

3,998

6,443

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock outstanding (in shares)

'

'

'

'

'

'

'

939,612

'

'

'

'

'

'

'

'

983,208

142,227

3,998

6,443

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Difference between the fair value of the new shares of Preferred Stock issued in the exchange and the carrying value of the Old Preferred Stock shares

'

60,937,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recapitalization amount allocated

'

60,981,000

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,269,000

[1]

52,712,000

[1]

-60,000

[1]

-108,425,000

[1]

'

'

'

'

'

'

'

'

'

'

'

Number of shares that can be purchased for warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

818

'

'

1,636

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants (in dollars per unit)

'

'

'

$76.27

$81.42

'

$81.42

'

'

'

'

'

'

$76.27

$76.27

$81.42

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants issued (in dollars)

$1,945,000

'

$830,000

'

$35,000

'

$68,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiration term of warrants

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

The recapitalization includes the exchange of Series A, Series B and Series C shares for Series A-4, Series A-3, and Series A-2 shares, respectively, in addition to the 1:10 exchange of Series A-2, Series A-3, and Series A-4 preferred stock, which occurred in conjunction with the Merger, and is more fully described in note 4.

Marketable_Securities_Details

Marketable Securities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
In Thousands, unless otherwise specified	item	item			Maximum	Domestic corporate commercial paper	Cash	Cash	Money market	Money market	Domestic corporate commercial paper
Available-for-sale marketable securities	'	'	'	'	'	'	'	'	'	'	'
Cash and cash equivalents, Carrying Value	$12,303	$18,653	$25,128	$10,582	'	'	$2,710	$1,134	$9,593	$16,020	$1,499
Cash and cash equivalents, Fair Value	12,303	18,653	'	'	'	'	2,710	1,134	9,593	16,020	1,499
Marketable securities, Amortized Cost	'	4,000	'	'	'	4,000	'	'	'	'	'
Marketable securities, Fair Value	'	$4,000	'	'	'	$4,000	'	'	'	'	'
Debt securities held in an unrealized loss position for more than 12 months	0	0	'	'	'	'	'	'	'	'	'
Debt securities held in an unrealized loss position for less than 12 months	0	0	'	'	'	'	'	'	'	'	'
Marketable securities, contractual term to maturity	'	'	'	'	'1 year	'	'	'	'	'	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property and Equipment	'	'
Property and equipment, gross	$859	$857
Less accumulated depreciation and amortization	-783	-718
Net Property Plant and Equipment	76	139
Furniture and fixtures	'	'
Property and Equipment	'	'
Estimated Useful Life	'5 years	'
Property and equipment, gross	68	68
Computer equipment and software	'	'
Property and Equipment	'	'
Estimated Useful Life	'3 years	'
Property and equipment, gross	286	284
Leasehold improvements	'	'
Property and Equipment	'	'
Property and equipment, gross	$505	$505

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Expenses and Other Current Liabilities	'	'
Research costs	$19,597	$6,558
Payroll and employee benefits	1,005	962
Professional fees	426	399
Vacation	69	129
Accrued interest on notes payable	852	595
Other	58	97
Total accrued expenses and other current liabilities	$22,007	$8,740

Loan_and_Security_Agreement_De

Loan and Security Agreement (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

23-May-11

Dec. 31, 2013

31-May-13

Dec. 31, 2013

23-May-11

Dec. 31, 2013

Nov. 21, 2011

Dec. 31, 2013

29-May-12

Term Loan

Term Loan

Term Loan

Term Loan

Term Loan A

Term Loan A

Term Loan B

Term Loan B

Term Loan C

Term Loan C

Series A-1 preferred stock

Series A-1 preferred stock

item

item

item

Loan and Security Agreement

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing limit

'

'

'

$25,000,000

'

'

'

'

'

'

'

'

Proceeds from note payable, net

'

'

'

'

'

'

'

6,300,000

'

6,300,000

'

'

Expected additional borrowings

'

'

'

'

'

'

'

'

'

'

'

12,500,000

Number of payments of principal and interest payable monthly in arrears

'

'

'

'

'

'

36

'

30

'

24

'

Final balloon payment

'

'

'

'

'

'

600,000

'

600,000

'

1,300,000

'

Annual interest rate (as a percent)

'

'

'

'

'

'

10.16%

'

10.00%

'

10.00%

'

Final payment fee (as a percent)

'

'

3.50%

'

'

'

'

'

'

'

'

'

Prepayment fees as percentage of amount prepaid if the prepayment occurs prior to the first anniversary of the funding

'

'

3.00%

'

'

'

'

'

'

'

'

'

Prepayment fees as percentage of amount prepaid if prepayment occurs between the first and second anniversary of the funding

'

'

2.00%

'

'

'

'

'

'

'

'

'

Prepayment fees as percentage of amount prepaid if prepayment occurs on or after the second anniversary of the funding

'

'

1.00%

'

'

'

'

'

'

'

'

'

Interest rate increase upon event of default (as a percent)

'

'

5.00%

'

'

'

'

'

'

'

'

'

Number of shares that can be purchased for warrants issued

'

'

'

'

12,280

'

'

'

'

'

'

'

Exercise price of warrants (in dollars per unit)

'

'

'

'

$76.27

$81.42

'

'

'

'

'

'

Term of warrants

'

'

'

'

'10 years

'

'

'

'

'

'

'

Fair value of warrants issued (in dollars)

1,945,000

830,000

'

'

'

'

78,100

182,600

80,100

177,600

167,900

379,700

Payment of facility fees to lender

'

'

'

'

'

'

250,000

'

'

'

'

'

Payment of reimbursed costs to lender

'

'

'

'

'

'

117,000

'

18,000

'

31,000

'

Period of recognition of discount on issue of warrants

'

'

'

'

'

'

'42 months

'

'36 months

'

'30 months

'

Future principal payments under the Loan and Security Agreement

'

'

'

'

'

'

'

'

'

'

'

'

Current portion of Note payable

13,156,000

'

'

'

'

'

'

'

'

'

'

'

Discount on current portion of note payable

-151,000

'

'

'

'

'

'

'

'

'

'

'

Current portion of Note payable, net of discount

$13,005,000

$7,800,000

'

'

'

'

'

'

'

'

'

'

Convertible_Preferred_Stock_De

Convertible Preferred Stock (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

10-May-13

Apr. 23, 2013

Dec. 31, 2013

Dec. 31, 2013

10-May-13

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

In Millions, except Share data, unless otherwise specified

Series B

Series B

Series A-1

Series A-1

Series A-2

Series A-2

Series A-2

Series A-3

Series A-3

Series A-3

Series A-4

Series A-4

Series A-4

Series A-5

Series A-5

Series A-6

Series A-6

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Series B

Series B

Series B

Series B

Series B

Series A Convertible Preferred Stock

Series A-1

Series A-1

Series A-1

Series A-1

Series A-2

Series A-2

Series A-2

Series A-2

Series A-3

Series A-3

Series A-3

Series A-3

Series A-4

Series A-4

Series A-5

Series A-5

Series A-6

Series A-6

item

Minimum

Maximum

item

item

After payment in full of required Series B preferred dividends

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B preferred stockholders

Minimum

After payment in full of required Series B and A-1 preferred dividends

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B and Series A-1 preferred stockholders

Minimum

After payment in full of required Series B, Series A-1 and A-2 preferred dividends

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series A-1 and Series A-2 preferred stockholders

Minimum

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series A-1, Series A-2 , Series A-3, Series A-5 and Series A-6 preferred stockholders

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series A-1 and Series A-2 preferred stockholders

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series A-1 and Series A-2 preferred stockholders

Convertible Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount to be raised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued

701,235

0

939,612

939,612

983,208

983,208

'

142,227

142,227

'

3,998

3,998

'

6,443

6,443

496,111

0

1,137

700,098

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares authorized

980,000

980,000

1,000,000

1,000,000

983,213

983,213

'

142,230

142,230

'

4,000

4,000

'

7,000

7,000

800,000

800,000

'

'

'

'

980,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued for purchase of shares of common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,450,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants (in dollars per unit)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.14

$6.14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.1

43

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued for purchase of shares of common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,843

1,750,248

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price per share of convertible preferred stock (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$61.42

$61.42

'

'

'

$81.42

'

$81.42

'

$81.42

'

$81.42

'

$81.42

'

$81.42

'

$81.42

$81.42

$81.42

$81.42

$81.42

$81.42

Conversion price per share (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.14

'

'

'

$7.63

'

'

'

$7.63

'

'

'

$7.63

'

'

'

$8.14

'

$8.14

'

$8.14

'

Original conversion price per share (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8.14

'

'

'

$8.14

'

'

'

$8.14

'

'

'

'

'

'

'

'

'

Original preferred stock conversion ratio (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10

'

'

'

10

'

'

'

10

'

'

'

'

'

'

'

'

'

Preferred Stock conversion ratio (in shares)

'

'

'

'

'

'

0.1

'

'

0.1

'

'

0.1

'

'

'

'

'

'

10

'

'

'

10.675

'

'

'

10.675

'

'

'

10.675

'

'

'

10

'

10

'

10

'

Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70.00%

'

'

'

'

'

70.00%

'

'

'

70.00%

'

'

'

70.00%

'

'

'

'

'

'

Dividend rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

8.00%

'

'

'

8.00%

'

'

'

8.00%

'

'

'

'

'

'

'

'

Accrued dividend

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.40

'

'

'

$15

'

'

'

$18

'

'

'

$2.60

'

'

'

'

'

'

'

'

'

Number of times of original purchase price, which will be paid to the preferred stockholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of classes of stockholder voting rights, in the aggregate, for preferred stockholders, on an as-if converted basis, together with common stockholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Members of the Company's Board of Directors that can be elected by preferred stockholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Deficit_Details

Stockholders' Deficit (Details)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Stockholders' Deficit	'	'
Number of shares of common stock reserved	58,006	49,020
Conversion of New Series B Preferred Stock	'	'
Stockholders' Deficit	'	'
Number of shares of common stock reserved	9,800	'
Conversion of Series A-1 Preferred Stock	'	'
Stockholders' Deficit	'	'
Number of shares of common stock reserved	10,000	10,000
Conversion of Series A-2 Preferred Stock	'	'
Stockholders' Deficit	'	'
Number of shares of common stock reserved	9,832	9,832
Conversion of Series A-3 Preferred Stock	'	'
Stockholders' Deficit	'	'
Number of shares of common stock reserved	1,422	1,422
Conversion of Series A-4 Preferred Stock	'	'
Stockholders' Deficit	'	'
Number of shares of common stock reserved	40	40
Conversion of Series A-5 Preferred Stock	'	'
Stockholders' Deficit	'	'
Number of shares of common stock reserved	70	70
Conversion of Series A-6 Preferred Stock	'	'
Stockholders' Deficit	'	'
Number of shares of common stock reserved	8,000	8,000
Stock options and Warrants	'	'
Stockholders' Deficit	'	'
Number of shares of common stock reserved	18,842	19,656

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
	item
Assets	'	'
Cash	$12,303,000	$18,653,000
Liabilities	'	'
Warrant liability	1,945,000	830,000
Number of work statements executed with the Nordic Work Statements	3	'
Level 3	'	'
Liabilities	'	'
Warrant liability	1,900,000	'
Stock liability	5,300,000	'
Recurring basis | Level 1	'	'
Assets	'	'
Cash	2,710,000	1,134,000
Money Market Funds	9,593,000	16,020,000
Assets fair value	12,303,000	17,154,000
Recurring basis | Level 2	'	'
Assets	'	'
Assets fair value	'	5,499,000
Recurring basis | Level 2 | Domestic corporate commercial paper	'	'
Assets	'	'
Money Market Funds	'	1,499,000
Marketable securities	'	4,000,000
Recurring basis | Level 3	'	'
Assets	'	'
Stock asset	'	407,000
Assets fair value	'	407,000
Liabilities	'	'
Warrant liability	1,945,000	830,000
Other liability	'	24,387,000
Stock liability	5,328,000	245,000
Total liabilities carried at fair value	7,273,000	25,462,000
Recurring basis | Estimated Fair Value	'	'
Assets	'	'
Cash	2,710,000	1,134,000
Money Market Funds	9,593,000	16,020,000
Stock asset	'	407,000
Assets fair value	12,303,000	23,060,000
Liabilities	'	'
Warrant liability	1,945,000	830,000
Other liability	'	24,387,000
Stock liability	5,328,000	245,000
Total liabilities carried at fair value	7,273,000	25,462,000
Recurring basis | Estimated Fair Value | Domestic corporate commercial paper	'	'
Assets	'	'
Money Market Funds	'	1,499,000
Marketable securities	'	$4,000,000

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
			Significant unobservable inputs	Preferred Stock	Preferred Stock	Preferred Stock	Preferred Stock	Preferred Stock
				Significant unobservable inputs	Significant unobservable inputs	Significant unobservable inputs	Significant unobservable inputs	Significant unobservable inputs
				PWERM	PWERM	PWERM	Market Comparable Companies	Market Comparable Companies
				Minimum	Maximum	Average	Minimum	Maximum
Quantitative information about the Company's Level 3 fair value measurements	'	'	'	'	'	'	'	'
Time until future exit event	'	'	'	'0 years	'4 months 24 days	'	'	'
Probability of abaloparatide coming to market	'	'	'	65.00%	75.00%	'	'	'
Discount rate (as a percent)	'	'	'	20.00%	40.00%	'	'	'
Long-term revenue growth rate (as a percent)	'	'	'	2.00%	117.00%	27.00%	'	'
Long-term pre-tax operating margin (as a percent)	'	'	'	13.00%	79.00%	68.00%	'	'
Discount for lack of marketability (as a percent)	'	'	'	10.00%	36.00%	'	'	'
Revenue multiple	'	'	'	'	'	'	3.2	8
Revenue years used in calculation of average estimated long-term revenue growth rate	'	'	'	'	'	'16 years	'	'
Years used in calculation of average estimated long-term pretax operating margin	'	'	'	'	'	'17 years	'	'
Warrant liability	$1,945,000	$830,000	$1,900,000	'	'	'	'	'
Stock liability	'	'	$5,300,000	'	'	'	'	'

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Roll-forward of the fair value of the assets, where fair value is determined by Level 3 inputs	'	'
Balance at the beginning of the period	$407	$3,379
Expense recognized	-313	-4,080
Additions	86	398
Change in fair value	-180	710
Balance at the end of the period	'	407
Roll-forward of the fair value of the liabilities, where fair value is determined by Level 3 inputs	'	'
Balance at the beginning of the period	25,462	10,920
Issuance of shares of Series A-6	-23,168	'
Additions	14,246	11,763
Change in fair value	-9,267	2,779
Balance at the end of the period	$7,273	$25,462

License_Agreements_Details

License Agreements (Details)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

11-May-11

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2005

17-May-11

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

Series A-1 Convertible Preferred Stock

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

USD ($)

USD ($)

USD ($)

USD ($)

Series A-1 Convertible Preferred Stock

Series A-1 Convertible Preferred Stock

Minimum

Minimum

Maximum

Maximum

Sublicense Agreement

USD ($)

USD ($)

EUR (€)

USD ($)

EUR (€)

Minimum

License Agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Nonrefundable, non-creditable payment

'

'

'

'

'

'

'

'

$250,000

'

'

'

'

'

'

'

Additional payments to be made upon achievement of certain development and commercialization milestones

'

'

'

'

'

'

'

'

'

'

'

13,800,000

10,000,000

49,600,000

36,000,000

'

Royalty rate (as a percent)

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

Period after the date of the first commercial sale of the product for license expiration

'

'

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'

'10 years

Amount recorded in research and development expense

$60,536,000

$54,961,000

$36,179,000

'

'

$200,000

$700,000

$1,000,000

'

'

$1,400,000

'

'

'

'

'

Number of days prior to closing on which shares issuable was determined based upon the U.S. dollar exchange rate for Euro

'

'

'

'

'2 days

'

'

'

'

'

'

'

'

'

'

'

Issuance of preferred stock (in shares)

'

'

'

922,286

'

'

'

'

'

17,326

'

'

'

'

'

'

Fair value per share of preferred stock (in dollars per share)

'

'

'

'

'

'

'

'

'

'

$81.42

'

'

'

'

'

Research_Agreements_Details

Research Agreements (Details)

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Feb. 28, 2013

Feb. 28, 2013

Feb. 28, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Feb. 28, 2013

Feb. 28, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

17-May-11

Mar. 29, 2011

17-May-11

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Feb. 28, 2013

Feb. 28, 2013

Dec. 31, 2013

Dec. 06, 2013

Dec. 06, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 06, 2013

Dec. 06, 2013

USD ($)

USD ($)

USD ($)

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-TD Phase 2 Clinical Study

Abaloparatide-TD Phase 2 Clinical Study

Abaloparatide-TD Phase 2 Clinical Study

Abaloparatide-TD Phase 2 Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Pass-through costs

Pass-through costs

Pass-through costs

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-TD Phase 2 Clinical Study

Abaloparatide-TD Phase 2 Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

First Amendment

First Amendment

First Amendment

First Amendment

First Amendment

First Amendment

First Amendment

First Amendment

Second Amendment

Second Amendment

Second Amendment

Second Amendment

Second Amendment

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Letter of Intent

Letter of Intent

Letter of Intent

Letter of Intent

Letter of Intent

Letter of Intent

Maximum

Maximum

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

USD ($)

USD ($)

USD ($)

item

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Nordic

Nordic

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-SC Phase 3 Clinical Study

Abaloparatide-TD Phase 2 Clinical Study

Abaloparatide-TD Phase 2 Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

USD ($)

EUR (€)

USD ($)

USD ($)

Maximum

Maximum

Series A-6

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Maximum

Maximum

item

United States

United States

United States

India

India

India

Per patient costs for enrolled patients

item

USD ($)

EUR (€)

Maximum

Maximum

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

item

USD ($)

EUR (€)

Maximum

USD ($)

EUR (€)

item

Maximum

Maximum

item

Maximum

Maximum

USD ($)

EUR (€)

Series A-5

Series A-5

Series A-5

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

USD ($)

EUR (€)

USD ($)

EUR (€)

Maximum

Maximum

USD ($)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

Former Operating Company

USD ($)

Maximum

Maximum

Minimum

Minimum

USD ($)

Maximum

Maximum

Minimum

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

Research Agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of countries where study was to be conducted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of additional countries where study will be conducted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of additional study sites

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Final payments, number of euro-denominated installments

'

'

'

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Final payments, number of U.S dollar-denominated installments

'

'

'

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of euro-denominated payments required over the course of Clinical Study

'

'

'

$56,700,000

€ 41,200,000

'

'

$5,000,000

€ 3,600,000

'

'

'

'

'

'

'

'

'

'

'

'

$6,200,000

€ 4,500,000

'

'

$1,700,000

€ 1,200,000

'

$988,919

€ 717,700

'

'

'

'

$5,100,000

€ 3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,100,000

€ 3,000,000

Amount of U.S. dollar-denominated payments required over the course of Clinical Study

'

'

'

3,200,000

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

'

143,369

'

'

289,663

'

'

'

'

'

205,540

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

Value of shares agreed to be purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

371,864

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price per share of convertible preferred stock (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8.14

'

'

'

'

'

$8.14

'

$8.14

'

'

'

$8.14

'

'

'

'

'

'

Additional term provided for standard-of-care treatment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'18 months

'18 months

'

'

'

'

Dividend declared (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

438,124

'

'

'

32,215

'

25,772

'

'

'

'

'

'

'

'

'

Shares sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

64,430

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

525,154

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares exchanged in the Merger

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,443

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate value of quarterly stock dividends, payable in shares

'

'

'

'

'

'

'

'

'

2,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,700,000

36,800,000

'

'

'

'

6,200,000

4,500,000

'

'

'

'

'

4,100,000

3,000,000

Aggregate U.S. dollar value of quarterly stock dividends, payable in shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

500,000

'

Number of shares due to the counter party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

438,124

'

'

'

32,215

'

25,772

'

'

'

'

'

'

'

'

'

Number of shares due to the counter party after conversion of stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,381,240

'

'

'

322,150

'

257,720

'

'

'

'

'

'

'

'

'

Amount reflected in accrued expenses and other current liabilities resulting from services payable in cash

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,600,000

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

Amounts reflected in accrued expenses and other current liabilities resulting from services payable in stock

'

'

'

'

'

4,800,000

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of initial payments for Euro-denominated installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

222,573

1,100,000

806,468

'

'

Period for which research and development expense is recognized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 months

'

'

'9 months

'

'9 months

'

'

'

'

'

'

'

'

'

'19 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development expense

60,536,000

54,961,000

36,179,000

'

'

'

'

'

'

'

'

3,900,000

6,000,000

5,000,000

'

31,600,000

30,800,000

5,100,000

4,100,000

1,400,000

4,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction in amount of euro-denominated payments required over the course of clinical study

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,454

11,941

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development expense related to costs incurred for preparatory and other start-up costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$11,000,000

'

$900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockbased_Compensation_Detail

Stock-based Compensation (Details) (USD $)	12 Months Ended				10 Months Ended		12 Months Ended		10 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Nov. 06, 2011	Nov. 06, 2011	Dec. 31, 2013	Dec. 31, 2013	Nov. 06, 2011	Dec. 31, 2013
		Stock option	Stock option	Stock option	Stock option	Stock option	Stock option	Stock option	Stock option	Stock option
					Stock option / 2003 Incentive Plan	Stock option / 2003 Incentive Plan	Stock option / 2003 Incentive Plan	Stock option / 2011 Incentive Plan	Stock option / 2011 Incentive Plan	Stock option / 2011 Incentive Plan
						Minimum	Minimum		Minimum	Minimum
Stock-based Compensation	'	'	'	'	'	'	'	'	'	'
Number of shares of common stock authorized for issuance	7,772,000	'	'	'	2,016,000	'	'	5,756,000	'	'
Options outstanding (in shares)	'	3,801,000	3,899,000	'	'	'	'	'	'	'
Number of shares available for grant	3,267,000	'	'	'	'	'	'	'	'	'
Exercise price of options as percentage of fair value of common stock on the date of grant	'	'	'	'	'	100.00%	100.00%	'	100.00%	100.00%
Exercise price of options as percentage of fair value of common stock on the date of grant in case of options granted to stockholder owning in excess of 10% of Company's common stock	'	'	'	'	'	110.00%	110.00%	'	110.00%	110.00%
Percentage of ownership required in entity's common stock for specified exercise price	'	'	'	'	'	10.00%	'	'	10.00%	10.00%
Exercise period	'	'	'	'	'10 years	'	'	'10 years	'	'
Exercise period in case of stock options granted to stockholder owning in excess of 10% of the company's common stock	'	'	'	'	'5 years	'	'	'5 years	'	'
Award vesting period	'	'	'	'	'4 years	'	'	'4 years	'	'
Weighted-average assumptions used in estimation of grant date fair values	'	'	'	'	'	'	'	'	'	'
Expected term	'	'6 years 3 months	'6 years 3 months	'6 years 3 months	'	'	'	'	'	'
Volatility (as a percent)	'	62.00%	60.00%	60.00%	'	'	'	'	'	'
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%	0.00%	'	'	'	'	'	'
Risk-free interest rates (as a percent)	'	2.45%	1.10%	1.35%	'	'	'	'	'	'
Summary of stock option activity - Shares	'	'	'	'	'	'	'	'	'	'
Options outstanding at the beginning of the period (in shares)	'	3,899,000	'	'	'	'	'	'	'	'
Granted (in shares)	'	2,427,000	'	'	'	'	'	'	'	'
Exercised (in shares)	'	-12,000	'	'	'	'	'	'	'	'
Forfeited (in shares)	'	-2,502,000	'	'	'	'	'	'	'	'
Expired (in shares)	'	-11,000	'	'	'	'	'	'	'	'
Options outstanding at the end of the period (in shares)	'	3,801,000	3,899,000	'	'	'	'	'	'	'
Options exercisable at the end of the period (in shares)	'	2,475,000	'	'	'	'	'	'	'	'
Options vested and expected to vest at the end of the period (in shares)	'	3,727,000	'	'	'	'	'	'	'	'
Summary of stock option activity - Weighted-Average Exercise Price (in dollars per share)	'	'	'	'	'	'	'	'	'	'
Options outstanding at the beginning of the period (in dollars per share)	'	$3.10	'	'	'	'	'	'	'	'
Granted (in dollars per share)	'	$3.45	'	'	'	'	'	'	'	'
Exercised (in dollars per share)	'	$1.10	'	'	'	'	'	'	'	'
Forfeited (in dollars per share)	'	$3.47	'	'	'	'	'	'	'	'
Expired (in dollars per share)	'	$1.50	'	'	'	'	'	'	'	'
Options outstanding at the end of the period (in dollars per share)	'	$3.09	$3.10	'	'	'	'	'	'	'
Options exercisable at the end of the period (in dollars per share)	'	$2.73	'	'	'	'	'	'	'	'
Options vested and expected to vest at the end of the period (in dollars per share)	'	$3.08	'	'	'	'	'	'	'	'
Weighted-Average Contractual Life (In Years)	'	'	'	'	'	'	'	'	'	'
Options outstanding at the end of the period	'	'7 years 25 days	'	'	'	'	'	'	'	'
Options exercisable at the end of the period	'	'6 years 7 months 6 days	'	'	'	'	'	'	'	'
Options vested and expected to vest at the end of the period	'	'7 years 22 days	'	'	'	'	'	'	'	'
Aggregate Intrinsic Value	'	'	'	'	'	'	'	'	'	'
Options outstanding at the end of the period (in dollars)	'	$2,283,000	'	'	'	'	'	'	'	'
Options exercisable at the end of the period (in dollars)	'	2,231,000	'	'	'	'	'	'	'	'
Options vested and expected to vest at the end of the period (in dollars)	'	2,280,000	'	'	'	'	'	'	'	'
Additional disclosures	'	'	'	'	'	'	'	'	'	'
Weighted-average grant-date fair value (in dollars per share)	'	$2.05	$2.36	$2.07	'	'	'	'	'	'
Total grant date fair value of stock options vested	'	1,800,000	1,500,000	'	'	'	'	'	'	'
Aggregate intrinsic value of options vested during the period	'	$20,000	$900,000	'	'	'	'	'	'	'

Stockbased_Compensation_Detail1

Stock-based Compensation (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of stock-based compensation expense	'	'	'
Share-based compensation expense included in operating expenses	$1,508,000	$1,795,000	$304,000
Total unrecognized compensation expense	2,600,000	'	'
Weighted average period over which unrecognized compensation is expected to be recognized	'2 years	'	'
Research and development	'	'	'
Summary of stock-based compensation expense	'	'	'
Share-based compensation expense included in operating expenses	302,000	338,000	118,000
General and administrative	'	'	'
Summary of stock-based compensation expense	'	'	'
Share-based compensation expense included in operating expenses	$1,206,000	$1,457,000	$186,000

Net_Loss_Per_Share_Details

Net Loss Per Share (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Numerator:	'	'	'
Net loss	($60,690)	($69,128)	($42,476)
Extinguishment of preferred stock	'	'	60,937
Accretion of Preferred Stock	-17,471	-13,992	-10,933
Earnings attributable to participating preferred stockholders	'	'	-7,275
Earnings (loss) attributable to common stockholders - basic	-78,161	-83,120	253
Earnings (loss) attributable to common stockholders - diluted	($78,161)	($83,120)	$253
Denominator:	'	'	'
Weighted-average number of common shares used in (loss) earnings per share - basic	874,004	839,698	499,944
Effect of dilutive options to purchase common stock (in shares)	'	'	464,933
Effect of dilutive convertible preferred stock (in shares)	'	'	2,489,399
Weighted-average number of common shares used in (loss) earnings per share - diluted	874,004	839,698	3,454,276
(Loss) earnings per share - basic (in dollars per share)	'	'	'
(Loss) earnings per share - basic (in dollars per share)	($89.43)	($98.99)	$0.51
Effect of dilutive options to purchase common stock (in dollars per share)	'	'	($0.24)
Effect of dilutive convertible preferred stock (in dollars per share)	'	'	($0.20)
(Loss) earnings per share - diluted (in dollars per share)	($89.43)	($98.99)	$0.07

Net_Loss_Per_Share_Details_2

Net Loss Per Share (Details 2)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Convertible preferred stock	'	'	'
Net Loss Per Share	'	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	11,315,006	4,834,687	5,419,946
Options to purchase common stock	'	'	'
Net Loss Per Share	'	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	3,976,072	3,890,911	894,160
Warrants	'	'	'
Net Loss Per Share	'	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	1,225,221	15,000	8,860

Income_Taxes_Details

Income Taxes (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Federal	'
Income Taxes	'
Net operating loss carryforwards	$263.60
State	'
Income Taxes	'
Net operating loss carryforwards	$229.40

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Federal	'
Income Taxes	'
Tax credits	$4
State	'
Income Taxes	'
Tax credits	$0.50

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations	'	'	'
Income tax benefit using U.S. federal statutory rate	($20,635)	($23,504)	($14,509)
State income taxes, net of federal benefit	-2,255	-2,774	-1,854
Stock-based compensation	92	72	49
Research and development tax credits	-1,277	-55	-385
Change in the valuation allowance	27,194	25,175	17,041
Permanent items	-3,085	709	91
Other	-34	377	-433
Income tax expense (benefit)	0	'	'
Current assets:	'	'	'
Accrued expenses	351	343	'
Deferred Rent	9	'	'
Gross current deferred tax assets	360	343	'
Valuation allowance	-360	-343	'
Net current deferred tax assets	0	'	'
Non-current assets:	'	'	'
Net operating loss carryforwards	100,284	74,487	'
Capitalized research and development	662	1,042	'
Research and development credits	4,345	3,067	'
Depreciation and amortization	110	90	'
Other	1,313	851	'
Gross non-current deferred tax assets	106,714	79,537	'
Valuation allowance	-106,714	-79,537	'
Net non-current deferred tax assets	0	'	'
Unrecognized tax benefits	0	'	'
Interest and penalties accrued	$0	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	0 Months Ended	12 Months Ended
	Jan. 14, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies	'	'	'	'
Monthly rental payments under the sublease	$9,000	'	'	'
Monthly rentals payable for the first 12 months	'	'	'	15,000
Monthly rentals payable for the subsequent 24 months	'	'	'	16,000
Rent expense	'	$200,000	$200,000	$100,000

Related_Party_Transactions_Det

Related Party Transactions (Details) (Consulting Agreement, USD $)	0 Months Ended			0 Months Ended
	Oct. 02, 2013	Jul. 30, 2013	Jul. 24, 2013	Jan. 23, 2014
	Dr. Jovan-Embiricos	Dr. Jovan-Embiricos	Dr. Jovan-Embiricos	Orbit
				item
Related party transactions	'	'	'	'
Aggregate consulting fees agreed to be paid in cash	'	'	$160,000	$400,000
Aggregate consulting fees paid	80,000	80,000	'	'
Number of installments in which consulting fees is payable	'	'	'	4
Amount to be paid under each installment	'	'	'	$100,000
Period after completion of agreement term during which restriction apply	'	'	'	'1 year

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Feb. 24, 2014

Feb. 19, 2014

Feb. 14, 2014

Feb. 14, 2014

Feb. 28, 2014

Feb. 24, 2014

Feb. 14, 2014

Feb. 14, 2014

Feb. 19, 2014

Feb. 19, 2014

Feb. 19, 2014

In Millions, except Share data, unless otherwise specified

Series A-1

Series A-1

Series A-2

Series A-2

Series A-2

Series A-3

Series A-3

Series A-3

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Series B-2 Purchase Agreement

Series B-2 Purchase Agreement

Series B-2 Purchase Agreement

Series B-2 Purchase Agreement

Series B-2 Purchase Agreement

Series B-2 Purchase Agreement

Series B-2 Purchase Agreement

Series B-2 Purchase Agreement

Series B-2 Purchase Agreement

Series B-2 Purchase Agreement

Series B-2 Purchase Agreement

Maximum

Series B-2 Shares

Series B-2 Shares

Series B-2 Shares

Series B-2 Shares

Series A-1

Series A-2

Series A-3

Maximum

Subsequent Events

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount to be raised

'

'

'

'

'

'

'

'

'

'

'

$40.20

'

'

'

'

'

'

'

Number of shares authorized

1,000,000

1,000,000

983,213

983,213

'

142,230

142,230

'

'

'

'

'

'

'

'

655,000

'

'

'

Preferred stock par value (in dollars per share)

$0.00

$0.00

$0.00

$0.00

'

$0.00

$0.00

'

'

'

'

'

'

'

$0.00

'

'

'

'

Warrants issued for purchase of shares of common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

1,637,500

'

'

'

'

'

'

'

Exercise price of warrants (in dollars per unit)

'

'

'

'

'

'

'

'

'

'

$6.14

'

'

'

'

'

'

'

'

Preferred Stock conversion ratio (in shares)

'

'

'

'

0.1

'

'

0.1

'

'

'

'

'

'

10

'

10.908

10.908

10.908

Conversion price per share (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.14

'

$7.46

$7.46

$7.46

Dividend rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

Payments to preferred stockholders as percentage of original purchase price of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

150.00%

'

'

'

'

'

'

Original issuance price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$61.42

'

'

'

'

Proceeds from issuance of shares

'

'

'

'

'

'

'

'

$25.60

'

'

'

'

'

'

'

'

'

'

Number of shares issued

939,612

939,612

983,208

983,208

'

142,227

142,227

'

'

'

'

'

'

417,615

'

'

'

'

'

Warrants issued for purchase of shares of common stock (in shares)

'

'

'

'

'

'

'

'

1,044,039

'

'

'

'

'

'

'

'

'

'

Exercisable period for stock options following the Advisory period

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'